DataMeds AI, Inc. 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-42530 Wellgistics Health, Inc. (Exact Name of Registrant As Specified In Its Charter) Delaware 93-3264234 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 3000 Bayport Drive , Suite 950 Tampa , Florida 33607 (Address of Principal Executive Offices) (ZIP Code) (844) 203-6092 (Registrant’s telephone number, including area code) N/A (Former name, former address and former fiscal year, if changed since last report) Securities to be registered under Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share WGRX The Nasdaq Stock Market LLC (The NASDAQ Capital Market) Indicate by check mark whether the registrant (1) has filed reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the Company is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐ Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of August 19, 2025, there were 84,064,100 shares of the Company’s common stock, par value $ 0.0001 , issued and outstanding. TABLE OF CONTENTS Page Part I. Financial Information 3 Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited ) 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited) 6 Notes to Condensed Consolidated Financial Statements 7 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Quantitative and Qualitative Disclosures About Market Risk 39 Item 4. Controls and Procedures 39 Part II. Other Information 40 Item 1 Legal Proceedings 40 Item 1A Risk Factors 40 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 40 Item 3 Defaults Upon Senior Securities 40 Item 4 Mine Safety Disclosures 40 Item 5 Other Information 40 Item 6 Exhibits 41 Signatures 42 In this Quarterly Report on Form 10-Q (this “ Quarterly Report ”), all references to “Wellgistics Health, Inc.,” “Wellgistics Health,” “we,” “us,” “our” or the “Company” mean Wellgistics Health, Inc., and its wholly-owned subsidiaries, except where it is made clear that the term means only Wellgistics Health, Inc. The Company’s common stock, par value $0.0001 per share, is referred to as “common stock.” 2 PART I—FINANCIAL INFORMATION Item 1. Financial Statements. WELLGISTICS HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, December 31, 2025 2024 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 419,942 $ 1,028,336 Accounts receivable, related party 775,027 271,298 Accounts receivable, net 1,386,423 2,453,517 Inventories, net 9,031,143 9,518,608 Prepaid expenses 65,525 524 Due from related parties 1,249,888 1,021,000 Subscription receivable 581,695 - Deferred offering costs - 875,385 Total current assets 13,509,643 15,168,668 Property, plant and equipment, net 308,642 388,180 Capitalized software 2,023,076 1,618,017 Operating lease, right-of-use-assets 1,280,459 1,528,128 Goodwill 16,219,929 16,219,929 Other intangible assets, net 19,219,880 20,746,009 Note receivable 139,771 139,771 Other assets 1,438,607 1,438,940 Deposits 85,008 85,008 Total assets $ 54,225,015 $ 57,332,650 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 9,450,651 $ 6,308,754 Accounts payable, related party 25,500 25,500 Accounts payable 25,500 25,500 Accrued expenses and other current liabilities 5,466,166 4,320,417 Due to related parties 5,234,770 4,944,770 Due to seller 8,500,000 10,000,000 Due to related parties 5,234,770 4,944,770 Current portion of debt obligations, net of debt discount 13,180,200 11,927,816 Operating lease liabilities- current portion 546,255 519,490 Total current liabilities 42,403,542 38,046,747 Notes payable 10,100,000 10,100,000 Note payable, related party - 1,300,000 Note payable - 1,300,000 Loan payable - 55,085 Operating lease liabilities 816,218 1,096,372 Total liabilities $ 53,319,760 $ 50,598,204 Commitments and contingencies (Note 14) - - Stockholders’ equity: Common stock, $ 0.0001 par value, 500,000,000 shares authorized, 72,881,535 and 51,055,508 shares issued and 63,144,817 and 51,055,508 shares outstanding as of June 30, 2025 and December 31, 2024, respectively 6,315 5,105 Additional paid-in capital 49,759,467 16,486,501 Accumulated deficit ( 48,860,527 ) ( 9,757,160 ) Total stockholders’ equity 905,255 6,734,446 Total liabilities and stockholders’ equity $ 54,225,015 $ 57,332,650 See the accompanying notes to the unaudited condensed consolidated financial statements 3 WELLGISTICS HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) 2025 2024 2025 2024 Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net revenues $ 7,790,865 $ 44,540 $ 18,654,308 $ 44,540 Cost of revenues 7,285,113 47,148 17,455,915 47,148 Gross profit (loss) 505,752 ( 2,608 ) 1,198,393 ( 2,608 ) Operating expenses: General and administrative 4,859,949 570,408 36,032,869 650,172 Sales and marketing 343,383 - 408,600 - Depreciation and amortization 802,796 - 1,605,668 - Total operating expenses 6,006,128 570,408 38,047,137 650,172 Loss from operations ( 5,500,376 ) ( 573,016 ) ( 36,848,744 ) ( 652,780 ) Other income (expense) Interest expense, net ( 1,184,040 ) ( 1,309 ) ( 2,278,530 ) ( 4,667 ) Other income 11,952 - 23,907 - Total other expense, net ( 1,172,088 ) ( 1,309 ) ( 2,254,623 ) ( 4,667 ) Net loss before income taxes ( 6,672,464 ) ( 574,325 ) ( 39,103,367 ) ( 657,447 ) Provision for income taxes - - - - Net loss $ ( 6,672,464 ) $ ( 574,325 ) $ ( 39,103,367 ) $ ( 657,447 ) Net loss per common share - basic and diluted $ ( 0.11 ) $ ( 0.01 ) $ ( 0.69 ) $ ( 0.01 ) Weighted average common shares outstanding - basic and diluted 61,771,127 45,898,175 56,863,720 46,843,308 See the accompanying notes to the unaudited condensed consolidated financial statements 4 WELLGISTICS HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited) Additional Total Stockholders’ Common Stock Paid-In Accumulated Equity Shares Amount Capital Deficit (Deficit) Balance at December 31, 2023 44,720,000 $ 4,472 $ ( 3,972 ) $ ( 2,900,934 ) $ ( 2,900,434 ) Net loss - - - ( 83,122 ) ( 83,122 ) Balance at March 31, 2024 44,720,000 $ 4,472 $ ( 3,972 ) $ ( 2,984,056 ) $ ( 2,983,556 ) Founder’s initial contribution - - 10,000 - 10,000 Shares issued to employees 2,274,012 227 ( 227 ) - - Shares issued pursuant to business combination 173,961 17 399,983 - 400,000 Net loss - - - ( 574,325 ) ( 574,325 ) Balance at June 30, 2024 47,167,973 $ 4,717 $ 405,783 $ ( 3,558,381 ) $ ( 3,147,881 ) Balance at December 31, 2024 51,055,508 $ 5,105 $ 16,486,501 $ ( 9,757,160 ) $ 6,734,446 Common stock issued pursuant to public offering 888,889 89 3,999,911 - 4,000,000 Common stock issued pursuant to consulting agreements 152,000 15 543,505 - 543,520 Vested restricted stock granted to consultants 986,123 99 2,875,461 - 2,875,560 Vested restricted stock granted to directors 8,362,494 836 24,277,922 - 24,278,758 Vested restricted stock granted to employees 15,000 2 75,582 - 75,583 Offering costs - - ( 1,598,196 ) - ( 1,598,196 ) Net loss - - - ( 32,430,903 ) ( 32,430,903 ) Balance at March 31, 2025 61,460,014 $ 6,146 $ 46,660,685 $ ( 42,188,063 ) $ 4,478,768 Balance 61,460,014 $ 6,146 $ 46,660,685 $ ( 42,188,063 ) $ 4,478,768 Common stock issued pursuant to equity purchase agreement 1,155,030 116 1,149,301 - 1,149,417 Issuance of commitment shares under equity purchase agreement 152,000 15 594,305 - 594,320 Common stock issued in partial settlement of seller’s note 333,333 33 1,499,967 - 1,500,000 Vested restricted stock granted to employees 44,440 4 354,559 - 354,563 Offering costs - - ( 499,349 ) - ( 499,349 ) Net loss - - - ( 6,672,464 ) ( 6,672,464 ) Balance at June 30, 2025 63,144,817 $ 6,315 $ 49,759,467 $ ( 48,860,527 ) $ 905,255 Balance 63,144,817 $ 6,315 $ 49,759,467 $ ( 48,860,527 ) $ 905,255 See the accompanying notes to the unaudited condensed consolidated financial statements 5 WELLGISTICS HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) 2025 2024 Six Months Ended June 30, 2025 2024 Cash flows from operating activities: Net loss $ ( 39,103,367 ) $ ( 657,447 ) Adjustments to reconcile net loss to net cash used in operating activities: Allowance for credit losses 200,454 - Amortization of debt discount 33,411 - Stock-based compensation 28,708,643 - Depreciation 79,538 - Amortization 1,526,129 12,794 Changes in operating assets and liabilities: Accounts receivable 362,911 ( 64 ) Inventories 487,465 16,102 Prepaid expenses ( 65,001 ) - Deposits - ( 35,855 ) Other assets 332 - Accounts payable 3,141,897 ( 203,953 ) Accrued expenses and other liabilities 1,145,749 276,994 Operating lease liabilities, net ( 5,720 ) 22,114 Due from / to related parties, net 61,112 930,508 Net cash (used in) provided by operating activities ( 3,426,447 ) 361,193 Cash flows from investing activities: Cash acquired in business combinations - 30,255 Investments in capitalized software ( 405,059 ) ( 47,800 ) Net cash used in investing activities ( 405,059 ) ( 17,545 ) Cash flows from financing activities: Proceeds from promissory note 615,000 - Repayment of seller promissory note ( 137,141 ) - Proceeds from term loan 703,366 - Proceeds from revolving line of credit 17,146,000 - Repayments of revolving line of credit ( 18,697,494 ) - Proceeds from merchant cash advance 234,157 - Proceeds from common stock issued pursuant to equity purchase agreement 567,722 - Proceeds from common stock issued pursuant to public offering 4,000,000 - Offering costs ( 1,208,498 ) ( 288,037 ) Founder’s initial contribution - 10,000 Net cash provided by (used in) financing activities 3,223,112 ( 278,037 ) Net change in cash and cash equivalents ( 608,394 ) 65,611 Cash and cash equivalents at beginning of period 1,028,336 1,364 Cash and cash equivalents at end of period $ 419,942 $ 66,975 Supplemental disclosure of cash flow information: Cash paid for income taxes $ - $ - Cash paid for interest $ 1,477,713 $ - Supplemental disclosure of non-cash investing and financing activities: Subscription receivable $ 581,695 $ - Issuance of commitment shares under equity purchase agreement $ 594,320 $ - Common stock issued in partial settlement of seller’s note $ 1,500,000 $ - Common stock issued pursuant to business combination $ - $ 400,000 Debt assigned to related party $ - $ 250,000 See the accompanying notes to the unaudited condensed consolidated financial statements 6 WELLGISTICS HEALTH, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was initially organized in the name of Ayan Sponsors LLC on September 6, 2022. Subsequently the Company incorporated under the name Danam Health, Inc. (together with the subsidiaries below, the “Company”/ “us”/ “we”/ “our”) as a Delaware Corporation that was registered on November 15, 2022, The Company’s headquarters are in Tampa, Florida. In January 2023 and May 2023, the Company entered into separate definitive agreements with the owners of Wood Sage LLC (“ Wood Sage ”) and Wellgistics LLC, respectively, whereby the Company would acquire all of the respective outstanding membership interests of Wood Sage (the “ Wood Sage Acquisition ”)and Wellgistics, LLC (the “ Wellgistics Acquisition ”). In June 2024, the Company and Wood Sage entered into an amended and revised definitive agreement and closed on the Wood Sage Acquisition, thereby making Wood Sage a wholly owned subsidiary. In connection with the Wood Sage Acquisition, the Company acquired two of its operating subsidiaries, Alliance Pharma Solutions LLC d/b/a DelivMeds (n/k/a Wellgistics Tech & Hub, LLC) (“DelivMeds”)—a pharmaceutical technology hub—and Community Specialty Pharmacy, LLC (n/k/a Wellgistics Pharmacy, LLC) (“Wellgistics Pharmacy”)—a retail community specialty pharmacy. On August 30, 2024, the Company closed on the Wellgistics Acquisition, thereby making Wellgistics LLC—a company focused on wholesale operations including the distribution and fulfillment of certain pharmaceutical medications to a network of independent pharmacies meant to improve market access to and patient outcomes regarding the medications—a wholly owned subsidiary. As such, the Company currently exists as a holding company with Wood Sage as a directly held intermediate holding company subsidiary, Wellgistics Tech & Hub, LLC and Wellgistics Pharmacy, LLC as indirect operating subsidiaries, and Wellgistics, LLC as a direct operating subsidiary. On October 4, 2024, the Company changed its corporate name to “Wellgistics Health, Inc.” (referred as “Wellgistics Health/WGRX/”the Company”/ “we”/ “us”/ “our”“) by filing a duly authorized Certificate of Amendment to its Certificate of Incorporation. Initial Public Offering On February 20, 2025, the Company entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Craft Capital Management LLC as representatives of the several underwriters (the “ Underwriters ”), relating to the Company’s initial public offering (the “Offering” or “IPO”) of 888,889 shares of common stock, par value $ 0.0001 per share, at a public offering price of $ 4.50 per share, generating gross proceeds of approximately $ 4 million and net proceeds of approximately $ 3.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The shares of common stock were offered and sold pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-280945), originally filed with the U.S. Securities and Exchange Commission (the “Commission”) on July 22, 2024, and later amended (as amended, the “Registration Statement”). The Registration Statement was declared effective by the Commission on February 14, 2025. The closing of the Offering took place on February 24, 2025. A final prospectus describing the terms of the offering was filed with the Commission on February 21, 2025. The Company’s common stock commenced trading on the Nasdaq Capital Market LLC on February 21, 2025, under the symbol “WGRX”. The IPO generated net proceeds to the Company of approximately $ 3.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Company intends to use the net proceeds from the offering to increase its capitalization, provide financial flexibility, and enhance visibility into the marketplace as well as to create a public market for the common stock and for general corporate purposes, including establishing working capital, funding marketing initiatives, and facilitating capital expenditures. 7 Summary of Significant Accounting Policies A description of the Company’s significant accounting policies and other financial information is included in the Company’s audited consolidated financial statements filed on March 25, 2025, with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “ Form 10-K ”). These policies have been applied consistently in these unaudited condensed consolidated interim financial statements. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2025 and for the three and six months then ended. The accompanying unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2024 included in the Form 10-K with the SEC on March 25, 2025. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses reported in those condensed consolidated financial statements. Descriptions of our significant accounting policies are discussed in the notes to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2024. Management evaluates the related estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ significantly from those estimates and assumptions. Significant changes, if any, in those estimates and assumptions resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. Segment Reporting In accordance with Accounting Standards Codification (“ASC”) 280, Segment Reporting (“ASC 280”), we identify our operating segments according to how our business activities are managed and evaluated. ASC 280 establishes standards for companies to report financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance. The CODM has been identified as the Chief Executive Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating and reportable segment. The key measures of segment profit or loss reviewed by our CODM are revenue and operating costs. These metrics are reviewed and monitored by the CODM to manage and forecast cash. The CODM also reviews operating costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. See Note 12 for further detail. Concentration of Credit Risks and Major Customers Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and receivables. The Company places its cash and cash equivalents with financial institutions. Deposits are insured to Federal Deposit Insurance Corp limits. For the six months ended June 30, 2025, one customer accounted for approximately 15 % of total revenue. The Company’s reliance on this and other major customers presents a concentration risk. The loss of this customer or a significant reduction in their orders could have a material adverse effect on the Company’s financial performance. The Company continues to focus on efforts to diversify its customer base to mitigate such risks. 8 Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The financial and nonfinancial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The hierarchy is presented down into three levels based on the reliability of the inputs. Level 1 Quoted prices are available in active markets for identical assets or liabilities. Level 2 Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable pricing inputs that are generally less observable from objective sources, such as discounted cash flow models or valuations. The carrying amounts of cash, accounts receivable, note receivable, deposits, accounts payable, accrued liabilities and short-term debt approximate their fair value because of the short-term nature of these instruments. The carrying amount of long-term debt approximates fair value because the debt is based on current rates at which the Company could borrow funds with similar maturities. Accounts Receivable and Allowance for Credit Losses Accounts receivable are recorded at the net invoiced amount, net of allowance for credit losses, and do not bear interest. Expected credit losses include losses expected based on known credit issues with specific customers as well as a general expected credit loss allowance based on relevant information, including historical loss rates, current conditions, and reasonable economic forecasts that affect collectability. The Company reserves for any accounts receivable balances that are determined to be uncollectible in the allowance for credit losses. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered. Actual write-offs may be in excess of the Company’s estimated allowance. The Company uses a loss rate method to estimate its allowance for credit losses. The determination of the current expected credit loss rate begins with our review of historical loss experience as a percentage of accounts receivable. To determine the current allowance for credit losses, we combine the historical and expected credit loss rates and apply them to our period end accounts receivable. The Company provides for a 95 % - 100 % loss rate of the accounts receivable which are due over the period of 90 days. The Company recognized a provision for credit losses of $ 200,454 and $ 0 within general and administrative expenses for the six months ended June 30, 2025 and 2024, respectively. As of June 30, 2025 and December 31, 2024, allowance for credit losses was $ 1,111,824 and $ 940,596 , respectively. Inventories, Net Inventories are stated at the lower of cost and net realizable value. Cost is determined on a first in first out (“ FIFO ”) basis. Cost of inventory is determined as the sum of the applicable expenditures and charges directly or indirectly incurred in bringing an article to its existing condition and location. On a quarterly basis, we evaluate inventory for net realizable value using estimates based on historical experience, current or projected pricing trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. If actual conditions are less favorable than our assumptions, additional inventory write-downs may be required, and no reserve is maintained as obsolete or expired inventories are written off. We believe that the inventory valuation provides a reasonable approximation of the current value of inventory. 9 Capitalized Software The Company complies with the guidance of ASC 350-40, “ Intangibles—Goodwill and Other—Internal Use Software ”, in accounting for our internally developed system projects that it utilizes to provide our services to customers. These system projects generally relate to software of the Company that is not intended for sale or otherwise marketed. Internal and external costs incurred during the preliminary project stage are expensed as they are incurred. Once a project has reached the development stage, the Company capitalizes direct internal and external costs until the software is substantially complete and ready for our intended use. Costs for upgrades and enhancements are capitalized, whereas costs incurred for maintenance are expensed as incurred. These capitalized software costs are amortized on a project-by-project basis over the expected economic life of the underlying software on a straight-line basis, which is generally three to five years. Amortization commences when the software is available for our intended use . As of June 30, 2025 and December 31, 2024, the Company capitalized $ 2,023,076 and $ 1,618,017 , respectively, in software development pertaining to the Delivmeds platform via its DelivMeds subsidiary. To date, the Delivmeds platform is not yet been placed in service and therefore amortization has not commenced. Revenue Recognition The Company recognizes revenue from contracts with customers under ASC 606, Revenue from Contracts with Customers (“ASC 606”). To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or services promised within each contract and determined those that were performance obligations, and assessed whether each promised good or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company recognizes revenue at the point of sale. The majority of orders are placed via the Company’s website. Customers generally pay by credit card at the time they place their order. The Company does have larger customers to whom they have extended terms for payment. Generally, payments from these customers are due within 30 days of their order being shipped. However, a few customers have been given terms extending out to 45 days. Distribution Wellgistics, LLC provides distribution and third party logistics services to both pharmaceutical manufacturers and independent retail pharmacies. The Company recognizes revenue when goods are delivered to the customer. The gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are considered when estimating the impact of these revenue deductions on gross sales for a reporting period. All revenue for the Company is recognized at the point-in-time when delivered to customer based on contractual obligations. Any amount collected from customers for goods not yet delivered is recorded as a contract liability. 10 Pharmacy The Company is in the retail pharmacy business, which fills prescriptions for medication written by a doctor and recognizes revenue at the time the patient confirms delivery of the prescription. Customer returns are not material. The following are the steps taken to recognize revenue. Step One: Identify the contract with the customer — The prescription is written by a doctor for a customer and delivered to the Company. The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers to the Customer the prescription, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for the reimbursement to the Company prior to filling of the prescription. Step Two: Identify the performance obligations in the contract — Each prescription is distinct to the Customer. Step Three: Determine the transaction price — The consideration is not variable. The transaction price is determined to be the price of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit managers, insurance companies and government agencies). Step Four: Allocate the transaction price — The price of the prescription invoiced represents the expected amount of reimbursement from third party payors. There is no difference between contract price and “stand-alone selling price”. Step Five: Recognize revenue when or as the entity satisfies a performance obligation — Revenue is recognized upon the delivery of the prescription. Disaggregation of Revenue The following is a summary of the disaggregation of revenue for the three and six months ended June 30, 2025 and 2024: SCHEDULE OF DISAGGREGATION OF REVENUE 2025 2024 2025 2024 Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Product revenue - distribution services $ 7,548,600 $ - $ 18,216,887 $ - Pharmacy retail sales 77,756 44,540 192,432 44,540 Third party logistics services 164,509 - 244,989 - Net revenues $ 7,790,865 $ 44,540 $ 18,654,308 $ 44,540 All revenue for the six months ended June 30, 2025 and 2024 were within the United States. Contract Assets and Liabilities Contract assets would include costs and services incurred on contracts with open performance obligations. These amounts would be included in contract assets on the condensed consolidated balance sheets. Contract liabilities include payment received for incomplete performance obligations and are included in contract liabilities on the condensed consolidated balance sheets. At June 30, 2025 and December 31, 2024, the Company had unearned revenue of 245,765 included in accrued expenses and other current liabilities. Goodwill Goodwill is an asset representing the excess cost over the fair market value of net assets acquired in business combinations. Goodwill is not amortized but is tested annually for impairment or on an interim basis when indicators of potential impairment exist. Goodwill is tested for impairment at the reporting unit level. The Company’s reporting units discrete financial information is available and management regularly reviews the operating results. For purposes of impairment testing, goodwill is allocated to the applicable reporting units based on the reporting structure. The Company has the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Qualitative factors assessed for each of the applicable reporting units include, but are not limited to, changes in macroeconomic conditions, industry and market considerations, cost factors, discount rates, competitive environments and financial performance of the reporting units. If the qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, a quantitative test is required. 11 The Company also has the option to proceed directly to the quantitative test. Under the quantitative impairment test, the estimated fair value of each reporting unit is compared to its carrying value, including goodwill. If the carrying value of the reporting unit including goodwill exceeds its fair value, an impairment charge equal to the excess would be recognized, up to a maximum amount of goodwill allocated to that reporting unit. During the three and six months ended June 30, 2025, the Company did not identify any events or changes in circumstances that would indicate potential impairment of goodwill. Accordingly, no goodwill impairment was recorded for the period. Impairment of Long-Lived Assets The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. When such events or changes in circumstances are present, the Company assesses the recoverability of long-lived assets by determining whether the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the total of the future cash flows is less than the carrying amount of those assets, the Company recognizes an impairment loss based on the excess of the carrying amount over the fair value of the assets. There were no triggering events to test intangibles for impairment loss during the three and six months ended June 30, 2025 and 2024. Leases The Company accounts for its leases under ASC 842, Leases . Under this guidance, arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both a right of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right of use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded when incurred. In calculating the right of use asset and lease liability, the Company has elected to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term. Offering Costs The Company complies with the requirements of ASC 340-10-S99-1. Prior to the completion of an offering, offering costs are capitalized if they are directly related to an equity financing that is probable of successful completion until such financing is consummated . The deferred offering costs are charged to stockholders’ equity upon the completion of an offering or to expense if the offering is abandoned, terminated, or significantly delayed in the period of determination. Deferred offering costs includes professional fees incurred including legal, accounting, underwriting and advisory services in connection with the Company’s equity offering. As of June 30, 2025 and December 31, 2024, the Company had capitalized $ 0 and $ 875,385 , respectively, in deferred offering costs. During the six months ended June 30, 2025, a total of $ 875,385 in previously capitalized offering costs was charged to stockholders’ equity upon the completion of the IPO. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation – Stock Compensation. The Company measures all stock-based awards granted to employees, directors and non-employee consultants based on the fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. For awards with service-based vesting conditions, the Company records the expense for using the straight-line method. For awards with performance-based vesting conditions, the Company records the expense if and when the Company concludes that it is probable that the performance condition will be achieved. The Company classifies stock-based compensation expenses in its statement of operations in the same manner in which the award recipient’s costs are classified. Net Loss per Share Net earnings or loss per share is computed by dividing net income or loss by the weighted-average number of common shares outstanding during the period, excluding shares subject to redemption or forfeiture. The Company presents basic and diluted net earnings or loss per share. Diluted net earnings or loss per share reflect the actual weighted average of common shares issued and outstanding during the period, adjusted for potentially dilutive securities outstanding. Potentially dilutive securities are excluded from the computation of the diluted net loss per share if their inclusion would be anti-dilutive. As all potentially dilutive securities are anti-dilutive as of June 30, 2025, diluted net loss per share is the same as basic net loss per share for each period. For the three and six months ended June 30, 2025 and 2024, the following items have been excluded from the computation of diluted net loss per share because the effect of including these would have been anti-dilutive: SCHEDULE OF POTENTIALLY DILUTIVE ITEMS OUTSTANDING 2025 2024 June 30, 2025 2024 Unvested restricted common stock issued not outstanding 10,070,051 - Total potentially dilutive shares 10,070,051 - 12 Recent Accounting Pronouncements In December 2023, Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosure s (“ASU 2023-09”). ASU 2023-09 focuses on income tax disclosures around effective tax rates and cash income taxes paid and requires public business entities to disclose, on an annual basis, a rate reconciliation presented in both dollars and percentages. The guidance requires the rate reconciliation to include specific categories and provides further guidance on disaggregation of those categories based on a quantitative threshold equal to 5 % or more of the amount determined by multiplying pretax income (loss) from continuing operations by the applicable statutory rate. For entities reconciling to the US statutory rate of 21 %, this would generally require disclosing any reconciling items that impact the rate by 1.05 % or more. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024 (generally, calendar year 2025) and effective for all other business entities one year later. Entities should adopt this guidance on a prospective basis, though retrospective application is permitted. The adoption of ASU 2023-09 is expected to have a financial statement disclosure impact only and is not expected to have a material impact on the Company’s condensed consolidated financial statements. In March 2024, the FASB issued ASU 2024-03, which provides new accounting guidance for certain crypto assets. Under the ASU, entities are required to subsequently measure qualifying crypto assets at fair value, with changes in fair value recognized in net income each reporting period. The ASU also establishes specific disclosure requirements, including information about significant crypto asset holdings, contractual sale restrictions, and changes in such holdings. The guidance applies to crypto assets that meet all of the following criteria: ● Meet the definition of intangible assets as defined in the ASC Master Glossary. ● Do not provide enforceable rights to or claims on underlying goods, services, or other assets. ● Are created or reside on a distributed ledger based on blockchain or similar technology. ● Are secured through cryptography. ● Are fungible. ● Are not created or issued by the reporting entity or its related parties. The ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2024-03 on its condensed consolidated financial statements. While the Company does not currently hold material amounts of crypto assets, it is assessing the implications of the guidance in the event of future crypto asset acquisitions or changes in investment strategy. Note 2. LIQUIDITY AND GOING CONCERN The Company had a net loss of $ 39,103,367 for the six months ended June 30, 2025 and an accumulated deficit of $ 48,860,527 as of June 30, 2025. Furthermore, the Company had net cash used in operating activities of $ 3,426,447 for the six months ended June 30, 2025. These factors raise a substantial doubt on whether the Company can continue as a going concern from the date these unaudited interim condensed consolidated financial statements are issued. The Company’s ability to continue as a going concern in the next twelve months following the date the condensed consolidated financial statements were available to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations and deploy such to produce profitable operating results. Management Plans On April 9, 2025, the Company entered into the Hudson Equity Purchase Agreement (“EPA”). Under the agreement, the Company may, at its discretion and subject to certain conditions, issue and sell shares of its common stock to Hudson over a 24-month commitment period, providing a potential source of additional capital to support the Company’s ongoing operations and growth initiatives. As of June 30, 2025, the Company had sold 1,155,030 shares of common stock under the Hudson EPA, resulting in net proceeds of $ 1,149,417 . The Company subsequently terminated the Hudson EPA effective August 13, 2025. There is no assurance, however, that the Company will be able to sell shares on favorable terms or that additional capital will be available from other sources when needed. If the Company is unable to obtain sufficient amount of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial condition, and operating results. The accompanying condensed consolidated financial statements do not include any adjustments that might result from these uncertainties. As a result of the above, in connection with our assessment of going concern considerations in accordance with FASB ASU 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that our liquidity condition raises substantial doubt about our ability to continue as a going concern through twelve months from the date these unaudited interim condensed consolidated financial statements are issued. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should we be unable to continue as a going concern 13 Note 3. ACCOUNTS RECEIVABLE, NET Accounts receivable, net consist of the following: SCHEDULE OF ACCOUNTS RECEIVABLE, NET June 30, December 31, 2025 2024 Third Party $ 2,498,247 $ 3,394,112 Affiliates 775,027 271,298 Total Accounts Receivable 3,273,274 3,665,410 Less: Allowance for credit losses ( 1,111,824 ) ( 940,596 ) Total accounts receivable, net $ 2,161,450 $ 2,724,814 Note 4. INVENTORIES, NET Inventory consists of the following: SCHEDULE OF INVENTORY June 30, December 31, 2025 2024 First Defense Nasal Screen Corp (“FDNS”) $ 6,005,624 $ 6,717,373 Finished goods 3,271,255 3,034,836 Total inventory, at cost 9,276,879 9,752,209 Less: reserve for obsolescence ( 245,736 ) ( 233,601 ) Inventories, net $ 9,031,143 $ 9,518,608 Note 5. PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment consist of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT, NET June 30, December 31, 2025 2024 Leasehold improvements $ 766,467 $ 766,467 Equipment 589,208 589,208 Furniture and fixtures 152,161 152,161 Property, plant and equipment, gross 1,507,836 1,507,836 Less: Accumulated depreciation ( 1,199,194 ) ( 1,119,656 ) Property, plant and equipment, net $ 308,642 $ 388,180 Depreciation expense for the three and six months ended June 30, 2025 and 2024 amounted to $ 39,731 , $ 0 , $ 79,538 and $ 0 , respectively. 14 Note 6. INTANGIBLE ASSETS Intangible assets consist of the following: SCHEDULE OF INTANGIBLE ASSETS June 30, December 31, 2025 2024 Software development costs - Delivmeds $ 2,023,076 $ 1,618,017 Customer relationships - Wood Sage acquisition 393,853 393,853 Customer relationships - Wellgistics acquisition 11,256,067 11,256,067 Trademark - Wellgistics acquisition 10,143,137 10,143,137 Intangible assets, gross 21,793,057 21,793,057 Accumulated amortization ( 2,573,177 ) ( 1,047,048 ) Intangible assets, net $ 19,219,880 $ 20,746,009 Intangible assets of $ 393,853 represent customer relationships identified and measured at fair value pursuant to the Wood Sage Acquisition in June 2024. The Company recorded amortization of $ 12,308 and $ 24,616 for the three and six months ended June 30, 2025, respectively, pertaining to these intangible assets. Intangible assets of $ 11,256,067 and $ 10,143,137 represent customer relationships and trademarks, respectively, identified and measured at fair value pursuant to the Wellgistics, LLC Acquisition in August 2024. The Company recorded amortization of $ 496,003 and $ 938,006 pertaining to customer relationships, and $ 281,754 and $ 563,508 pertaining to the trademark for the three and six months ended June 30, 2025, respectively. The following table represents the future amortization of intangibles assets: SCHEDULE OF FUTURE AMORTIZATION OF INTANGIBLES ASSETS Year Ended December 31, 2025 (remaining six months) $ 1,526,129 2026 3,052,258 2027 3,052,258 2028 3,052,258 2029 3,052,258 Thereafter 5,484,719 Intangible assets $ 19,219,880 15 Note 7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other liabilities consist of the following: SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, 2025 2024 Accrued personnel costs $ 3,426,314 $ 3,112,470 Accrued professional fees 139,557 347,829 Accrued expenses 227,973 - Credit card obligation 222,485 110,201 Unearned revenue 245,765 245,765 Accrued interest 1,204,072 504,152 Accrued expenses and other liabilities $ 5,466,166 $ 4,320,417 Note 8. DEBT Outstanding debt consists of the following: SCHEDULE OF OUTSTANDING DEBT June 30, December 31, 2025 2024 Merchant cash advance, net of debt discount $ 1,548,657 $ 1,259,415 Loan payable 703,366 - Note payable - sellers of Wellgistics 5,000,000 5,000,000 Note payable, net of debt discount 648,411 - Note payable – Integral Health 1,300,000 - Revolving line of credit 3,979,766 5,531,260 Seller promissory note - 137,141 Current portion of debt obligations 13,180,200 11,927,816 Merchant cash advance $ - $ 55,085 Third party investor 100,000 100,000 Note payable - Integral Health - 1,300,000 Note payable - sellers of Wellgistics 10,000,000 10,000,000 Long-term debt 10,100,000 11,455,085 Total debt $ 23,280,200 $ 23,382,901 As of June 30, 2025 and December 31, 2024, unamortized debt discount was $ 880,601 and $ 519,430 , respectively. Integral Health Inc. (“Integral Health”) On August 22, 2023, Wood Sage entered into a non-interest bearing promissory note (“Note”) with Integral Health, a then related party with common ownership and board members, pursuant to which Integral made a certain loan to Wood Sage in the amount of $ 1,300,000 to satisfy the purchase price under the agreements by which Wood Sage acquired Wellgistics Pharmacy and DelivMeds. No later than 30 days after a change in control to Wood Sage, the aggregate unpaid principal balance of the Note became due and payable by Wood Sage, which occurred upon the consummation of the Company’s acquisition of Wood Sage. As of the date of issuance of these condensed consolidated financial statements, the note is still outstanding and the parties mutually agreed for an extension. Merchant Cash Advance On March 18, 2025, the Company entered into a merchant cash advance agreement with a third-party lender. Pursuant to the agreement, the Company received gross funding of $ 1,900,000 in exchange for the sale of future receivables totaling $ 2,840,000 . Of the $ 1,900,000 in funding, $ 1,118,250 was directly applied by the lender to settle existing obligations under a prior agreement with the same lender, effectively refinancing the earlier balance. The remaining $ 781,750 was disbursed to the Company for working capital and operational needs. 16 The MCA Agreement resets the Purchased Amount (as defined), repayment terms, and structure under a new contract. The Company is obligated to remit weekly payments of $ 56,800 until the full Purchased Amount of $ 2,840,000 is repaid. The Company accounts for the merchant cash advance as a debt obligation. The Company recorded a liability equal to the full Purchased Amount of $ 2,840,000 , with a corresponding debt discount of $ 940,000 representing the difference between the repayment obligation and the net proceeds received. The debt discount will be amortized to interest expense over the term of the arrangement. As of June 30, 2025, the carrying amount of the loan, net of the remaining unamortized discount of $ 552,943 , was $ 1,548,657 . Loan Payable On May 14, 2025, the Company entered into a Business Loan and Security Agreement with Agile Capital Funding, LLC for a principal amount of $ 756,000 . The Company received $ 500,000 in cash proceeds and recorded a debt discount of $ 256,000 . The loan does not bear a stated interest rate; instead, the debt discount represents the implied borrowing cost. The loan matures in December 2025, and is repayable in weekly installments of $ 27,000 . The loan is secured by certain assets of the Company not otherwise secured in its other financing arrangements and was used for general working capital purposes. The Company is amortizing the debt discount using the effective interest method over the 28 week term. Amortization of debt discount recorded to interest expense was $ 45,542 for the three and six months ended June 30, 2025. As of June 30, 2025, the carrying amount of the loan, net of the remaining unamortized discount of $ 210,458 , was $ 464,542 . Cash Advance On June 25, 2025, the Company entered into an Agreement for the Purchase and Sale of Future Receipts with Agile Capital Funding, LLC for a total purchased amount of $ 367,200 . The Company received $ 255,000 in cash proceeds and recorded a debt discount of $ 112,200 . The agreement assigns 15% of proceeds of future sales to the buyer, with weekly repayment installments of $ 13,114 over 28 weeks based on estimated average monthly sales projections. Proceeds were used for general working capital purposes. The Company is amortizing the debt discount using the effective interest method over the 28 week term. As of June 30, 2025, the carrying amount of the arrangement, net of the remaining unamortized discount of $ 112,200 , was $ 238,824 . Note payable – owners of Wellgistics, LLC On August 23, 2024, the Company and the sellers of Wellgistics LLC entered into the Fourth Amendment to the Wellgistics MIPA. Pursuant to the amended agreement, Wellgistics Health agreed to pay Wellgistics LLC a promissory note in the aggregate principal amount of $ 15,000,000 plus simple interest accruing annually equal to the “Prime Rate” as published by the Wall Street Journal on January 1 of the applicable year, together payable in three equal annual installments commencing on the first anniversary of the date that IPO registration statement becomes effective. For 2025, the interest rate was 7.5 %. For the three and six months ended June 30, 2025, the Company recorded interest expense of $ 318,750 and $ 637,500 , respectively, pertaining to the note. As of June 30, 2025 and December 31, 2024, accrued interest on the note totaled $ 1,062,500 and $ 425,000 respectively, and is included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. As of June 30, 2025, $ 5,000,000 was included as a current liability on the consolidated balance sheet and the remaining $ 10,000,000 was classified as non-current. Note Payable – Third Party On January 2, 2025, the Company entered into an unsecured promissory note agreement for a principal amount of $ 448,411 . The promissory note bears interest at a rate of 10 % per annum, with both principal and accrued interest due in full on May 15, 2025. In the event of default, interest accrues at a default rate of 12 % per annum. In connection with this note, the Company received net proceeds of $ 415,000 , with the remaining $ 33,411 recognized as a debt discount. For the three months ended June 30, 2025, the Company recorded interest expense of $ 11,210 and amortization of debt discount of $ 11,304 related to this note. For the six months ended June 30, 2025, the Company recorded total interest expense of $ 22,021 and amortization of debt discount of $ 33,411 . As of June 30, 2025, accrued interest payable on this note was $ 22,021 , and the outstanding principal of $ 448,411 is classified under current liabilities. As of the issuance date of these condensed consolidated financial statements, the parties are currently working on an extension. On February 2, 2025, the Company entered into an unsecured promissory note agreement for a principal amount of $ 100,000 . The promissory note bears interest at a rate of 10 % per annum, with both principal and accrued interest due in full on August 15, 2025. In the event of default, interest accrues at a default rate of 12 % per annum. For the three months ended June 30, 2025, the Company recorded interest expense of $ 2,500 related to this note. For the six months ended June 30, 2025, the Company recorded total interest expense of $ 4,062 . As of June 30, 2025, accrued interest payable on this note was $ 4,062 , and the outstanding principal of $ 100,000 is classified under current liabilities. 17 On February 2, 2025, the Company entered into another unsecured promissory note agreement in the principal amount of $ 100,000 . The promissory note bears interest at a rate of 10 % per annum, with both principal and accrued interest due in full on August 15, 2025. In the event of default, interest accrues at a default rate of 12 % per annum. For the six months ended June 30, 2025, the Company recorded interest expense of $ 4,062 related to this promissory note. As of June 30, 2025, the outstanding principal of $ 100,000 is classified under current liabilities. As of the issuance date of these condensed consolidated financial statements, the parties are currently working on an extension. Note Payable – Related Party On April 7, 2025, the Company issued an unsecured promissory note (the “April 2025 Note”) to Sansur Associates, LLC, a related party entity beneficially owned by Surendra Ajjarapu, the Chairman of the Company’s Board of Directors, in the principal amount of $ 500,000 . The April 2025 Note bears interest at a rate of 10 % per annum and matures on October 7, 2025 . The Company may prepay any portion of the outstanding principal and accrued interest at any time without penalty. In the event of a default, the note provides for acceleration of the outstanding balance and an increase in the interest rate to 12 % per annum. As of June 30, 2025, the principal amount had not been funded and no interest expense had accrued. The April 2025 Note was subsequently canceled in August 2025. Revolving line of credit In November 2024, the Company entered into a new credit agreement for a line of credit of $ 10,000,000 . The new line of credit has interest annual rate equal to the Term Standard Overnight Financing Rate (“SOFR”) plus 11.5%, calculated and prorated daily on the daily balance (an aggregate rate of 16.84% per annum). The line of credit is collateralized by accounts receivable and inventory balances. Interest related to the line of credit amounted to $ 332,439 and $ 614,199 for the three and six months ended June 30, 2025, respectively. The outstanding balance on the line of credit as of June 30, 2025 and December 31, 2024 was $ 3,979,766 and $ 5,531,260 , respectively, which is included as a current liability on the condensed consolidated balance sheet. Seller Promissory Note - Wellgistics In May 2022, the Company entered into a promissory note agreement in the amount of $ 1.2 million. The promissory note was part of the consideration to the seller in connection with its acquisition of American Pharmaceutical Ingredients, LLC (a subsidiary of Wellgistics LLC). The promissory note bore interest at a rate of 2 % per annum and scheduled to mature on April 1, 2025. The Company assumed this debt as part of the Wellgistics Acquisition. As of June 30, 2025, the promissory note had been fully repaid, and the outstanding balance was $ 0 , compared to $ 137,141 as of December 31, 2024. Interest expense related to the promissory note was immaterial for the six months ended June 30, 2025. The following table is a summary of annual principal payments of the Company’s outstanding debt: SCHEDULE OF ANNUAL PRINCIPAL PAYMENTS December 31, 2025 $ 14,060,801 2026 5,100,000 2027 5,000,000 Principal Payment $ 24,160,801 18 Note 9. STOCKHOLDERS’ EQUITY Initial Public Offering On February 24, 2025, the Company closed its IPO of 888,889 shares of common stock at a public offering price of $ 4.50 per share. The IPO generated gross proceeds of $ 4.0 million and net proceeds of approximately $ 3.1 million after deducting underwriting discounts, commissions, and other offering expenses. Advisor and Consulting Agreements On February 25, 2025, the Company entered into a consulting agreement with Hudson to provide business advisory services, growth strategy guidance, and networking support for a 30-day period. As consideration for these services, the Company agreed to pay Hudson a cash fee of $ 250,000 and to issue 52,000 shares of restricted common stock. The Company recognized stock-based compensation expense of $ 0 and $ 143,520 during the three and six months ended June 30, 2025, respectively, in connection with the equity issuance. This expense was recorded within general and administrative expenses in the condensed consolidated statements of operations. The fair value of the restricted stock was determined based on the market price of the Company’s common stock on the grant date. On March 17, 2025, the Company entered into consulting agreement with Draper, Inc. (“ Draper ”), pursuant to which Draper agreed to provide investor relations and business development services. As consideration for services under the initial three-month term of the agreement, the Company issued 100,000 shares of restricted common stock to Draper. The consulting agreement automatically renews on a month-to-month basis unless terminated by either party with at least seven days’ notice prior to the end of the current term. The Company will be obligated to issue an additional 100,000 restricted shares of common stock for each renewal period. The Company subsequently terminated this consulting agreement on June 16, 2025. Based on the market price of the Company’s common stock on the grant date, the total fair value of the shares issued to Draper was determined to be $ 400,000 . For the three and six months ended June 30, 2025, the Company recognized stock-based compensation expense of $ 65,217 and $ 400,000 , respectively, in connection with this agreement. This expense was recorded within sales and marketing expenses in the condensed consolidated statements of operations. Directors and Former Employees As previously disclosed on the Company’s Current Report on Form 8-K filed with the SEC on April 11, 2025, the Company’s board of directors appointed Michael L. Peterson to fill the vacancy created as a result of the resignation of Sajid Sayed. In consideration for his board services and to further align his interests with those of the Company and its stockholders, the Company’s board of directors determined, after his appointment, to issue 200,000 restricted shares of the Company’s common stock that vest in equal amounts over a three-year period beginning on the first anniversary date of the grant. Vesting of Mr. Peterson’s shares of common stock accelerates if or when he leaves the Company. In June 2025, the Company also granted former chief executive officer Timothy Canning 750,000 restricted shares of the Company’s common stock in fulfillment of the sign-on bonus to which he had been entitled pursuant to the terms of his employment agreement with the Company. The shares vest on the six-month anniversary of the grant date. As previously disclosed on the Company’s Current Report on Form 8-K filed with the SEC on March 6, 2025, Mr. Canning tendered his resignation to the Company effective February 28, 2025. Equity Purchase Agreement On April 9, 2025, the Company entered into the Hudson EPA pursuant to which Hudson committed to purchase, upon the Company’s request, up to $ 50 million of the Company’s common stock over a 24-month period, subject to certain conditions. Under the terms of the agreement, the Company may, from time to time and at its sole discretion, issue “put notices” requiring Hudson to purchase shares at a price based on a formula tied to the market price of the Company’s common stock, as defined in the Hudson EPA. As of June 30, 2025, the Company had issued a total of 1,155,030 shares of common stock pursuant to put notices under the agreement, resulting in net proceeds of $ 1,149,417 . As of June 30, 2025, the Company had a subscription receivable of $ 581,595 pertaining to shares issued under the Hudson EPA for which proceeds were received in July 2025. In connection with entering into the Hudson EPA, the Company also issued 152,000 commitment shares to Hudson, which were valued at a fair value of $ 594,320 based on the closing price of the Company’s common stock on the agreement date. The amount was recorded as stock-based compensation and was included within general and administrative expenses in the condensed consolidated statements of operations. Wellgistics MIPA On April 14, 2025, the Company and sellers of Wellgistics LLC further amended the Wellgistics MIPA. Pursuant to the amendment, the portion of the closing cash payment payable to one of the sellers, Strategix Global LLC, was reduced by $ 1,500,000 , and in lieu of such payment, Strategix was issued 333,333 shares of the Company’s common stock. These shares will be subject to a 12-month lock-up period consistent with the terms applicable to management and large shareholders at the time of the Company’s IPO. 19 2023 Equity Incentive Plan The Company adopted the 2023 Equity Incentive Plan (the “Plan”), which provides the issuance of up to 43,506,064 shares of the Company’s common stock (the “Initial Limit”). Beginning on January 1, 2025, and on each January 1 thereafter, the number of shares reserved for issuance under the Plan will automatically increase by an amount equal to three percent (3%) of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31, or such lesser amount as may be determined by the Plan’s administrator (the “Annual Increase”). Shares issued under the Plan may be newly issued shares or reacquired shares. The Plan permits the grant of various types of stock-based awards, including incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards. The number of shares available for issuance as incentive stock options may not exceed the Initial Limit, as adjusted for any Annual Increases, subject to adjustment as provided under the terms of the Plan. Shares subject to awards that expire, are canceled, or otherwise terminate without having been exercised or settled in full will again become available for future grant under the Plan. However, shares repurchased by the Company on the open market will not be added back to the share reserve. Awards that may be settled solely in cash do not count against the share reserve. The Plan also includes a limitation on annual compensation to non-employee directors. The aggregate value of all equity awards granted to any non-employee director under the Plan, together with any cash compensation paid for service as a non-employee director, may not exceed (i) $ 1,000,000 in the first calendar year of service and (ii) $ 750,000 in any subsequent calendar year. The fair value of such awards is determined based on grant date fair value in accordance with ASC Topic 718, excluding the impact of estimated forfeitures related to service-based vesting conditions. Restricted Common Stock On February 28, 2025, in connection with the appointment of Brian Norton as Chief Executive Officer of the Company, Mr. Norton was granted and issued 9,000,000 shares of restricted common stock under the Company’s Amended and Restated 2023 Equity Incentive Plan (the “Plan”). These shares of restricted common stock vest in three equal annual installments over a three-year period, contingent upon the achievement of specified gross revenue and gross profit targets established by the Company’s Compensation Committee. As of June 30, 2025, none of the performance targets had been determined to be probable of achievement. Accordingly, no stock-based compensation expense was recognized in connection with this grant during the six months ended June 30, 2025. The Company will begin recognizing stock-based compensation expense on a prospective basis in the period in which the performance conditions are deemed probable of achievement. The shares were valued based on the market price of the Company’s common stock on the grant date. On March 14, 2025, the Company granted a total of 10,764,108 shares of restricted stock under the Plan to directors, employees, and consultants. The shares granted had varying vesting terms, ranging from immediate vesting to vesting over a five-year period. As of June 30, 2025, 9,560,057 of these shares had vested and are included in the total outstanding common stock reported in the consolidated statement of stockholders’ equity. As of June 30, 2025, a total of 134,000 shares were forfeited and cancelled and the remaining 10,070,051 shares were unvested as of June 30, 2025. A summary of information related to restricted common stocks for the six months ended June 30, 2025 is as follows: SCHEDULE OF RESTRICTED COMMON STOCKS Restricted Common Stock Weighted Average Grant Date Fair Value Unvested shares as of December 31, 2024 - - Granted 19,764,108 $ 2.90 Vested ( 9,560,057 ) $ 2.90 Forfeited and cancelled ( 134,000 ) $ 2.90 Unvested shares as of June 30, 2025 10,070,051 $ 2.90 For the three and six months ended June 30, 2025, the Company recognized $ 935,222 and $ 28,708,643 , respectively, in stock-based compensation expense in accordance with ASC 718, Compensation – Stock Compensation, based on the grant-date fair value of the restricted stock. For the three and six months ended June 30, 2025, stock-based compensation expense included in sales and marketing expense was $ 65,217 and $ 400,000 , respectively. For the three and six months ended June 30, 2025, stock-based compensation expense included in general and administrative expense was $ 870,005 and $ 28,308,643 , respectively. As of June 30, 2025, total unrecognized compensation expense related to the 10,070,051 non-vested restricted stock awards was $ 2,811,224 , which is expected to be recognized over a weighted-average period of 2.54 years. Total unrecognized compensation related to unvested performance-based shares was $ 26,100,000 as of June 30, 2025. 20 Note 10. LEASE OBLIGATIONS Rent is classified by function on the condensed consolidated statements of operations as general and administrative. The following is the summary of operating lease assets and liabilities: SCHEDULE OF OPERATING LEASE ASSETS AND LIABILITIES June 30, 2025 Operating Leases Right-of-use assets $ 1,280,459 Lease liabilities, current portion 546,255 Long-term lease liabilities 816,218 Total lease liabilities $ 1,362,473 Weighted Average Remaining Lease Term 2.43 Weighted Average Discount Rate 7.36 % The following is the summary of future minimum payments: SCHEDULE OF SUMMARY OF FUTURE MINIMUM PAYMENTS December 31, 2025 (remaining 6 months) $ 307,086 2026 621,530 2027 458,656 2028 84,977 Total lease payments 1,472,249 Less: Imputed interest ( 109,776 ) Total $ 1,362,473 Note 11. RELATED PARTY TRANSACTIONS The Company had transactions with Scienture Holdings, Inc. (f/k/a/ TrXade Health, Inc / TRG / TrXade Health / Scienture) and group which included Integra Pharma Solutions, LLC (“ IPS ”), in which board members of the Company were also members of Scienture’s management and board at the time the transactions occurred. Tollo Health, LLC acquired IPS from Scienture in April 2025. At that time Tollo Health, LLC was owned in part by Integral Health, Inc., in which certain board members of the Company also had a beneficial ownership interest. Integral Health acquired IPS from Tollo Health, LLC in June 2025. The common management between the entities at the time the transactions occurred classifies Scienture, IPS, and Integral as related parties. 21 Wellgistics, LLC was previously partly owned by a private equity company, Nomad Capital LLC, which has ownership interest in a few portfolio companies and Wellgistics, LLC had transactions with some of the affiliated companies of Nomad Capital. Operating expenses with affiliated companies, which include software expenses and marketing expenses, are recorded within general and administrative expenses. Cingo Solutions provides IT, cyber security and compliance services; and RxERP provides serialized ERP for pharma as a software-as-a-service (“ SaaS ”) to the Company. Wellgistics, LLC is charged a managerial service and software fee by Cingo and RxERP, respectively, which is recorded within general and administrative expenses. The Company had transactions with Scietech, LLC where a significant investor is the spouse of one of the directors of the Company, which qualifies as a related party. The following is a summary of due from and to related parties, as well as accounts receivable and accounts payable, as of June 30, 2025 and December 31, 2024: SCHEDULE OF SUMMARY OF DUE FROM AND TO RELATED PARTIES June 30, December 31, 2025 2024 Due from Integral Health/IPS * $ 1,214,911 $ - Due from TRG - 146,000 Due from Tollo** 34,977 - Due from IPS - 305,000 Due from Scienture Holdings - 570,000 Due from related parties $ 1,249,888 $ 1,021,000 Due to Integral Health/IPS * $ 5,234,770 $ - Due to TRG - 9,351 Due to IPS - 3,764,000 Due to Scienture Holdings - 1,171,419 Due to related parties $ 5,234,770 $ 4,944,770 * Integral Health acquired IPS in June 2025 and the parties are currently working on an agreement to settle the net balance owed by the Company for equity consideration. This is inclusive of the accounts receivable held by the Company to IPS as noted below. ** Tollo had common ownership with the Company’s significant stockholders and board members through June 2025. June 30, December 31, 2025 2024 Accounts receivable – IPS (Integral Health) $ 775,027 $ 271,298 Accounts receivable $ 775,027 $ 271,298 Accounts payable - Scietech $ 25,500 $ 25,500 Accounts payable $ 25,500 $ 25,500 The Company had the following transactions with related parties during the three and six months ended June 30, 2025 and 2024: SCHEDULE OF RELATED PARTY TRANSACTION 2025 2024 2025 2024 Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Sales to IPS $ - $ - $ 503,730 $ - Sales $ - $ - $ 503,730 $ - IT expenses paid to Cingo Solutions (common management) $ 38,440 $ - $ 199,440 $ - SaaS expenses paid to RxERP (common management) $ 150,000 - $ 150,000 - IT expenses paid $ 150,000 - $ 150,000 - Management services fees paid to Nomad Capital $ - $ - $ 160,000 $ - Management services fees paid $ - $ - $ 160,000 $ - Note 12. SEGMENT AND GEOGRAPHIC INFORMATION The Company operates as one operating segment. The Company’s CODM is its chief executive officer, who reviews financial information presented on a consolidated basis. The CODM uses consolidated gross margin, operating income and net income to assess financial performance and allocate resources. These financial metrics are used by the CODM to make key operating decisions, such as the determination of the rate at which the Company seeks to grow operating income and the allocation of budget between cost of revenues, sales and marketing, general and administrative expenses or technology and development. The following table presents selected financial information with respect to the Company’s single operating segment for the three and six months ended June 30, 2025 and 2024: SCHEDULE OF SEGMENT AND GEOGRAPHIC INFORMATION Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Net revenues $ 7,790,865 $ 44,540 $ 18,654,308 $ 44,540 Cost of net revenues 7,285,113 47,148 17,455,915 47,148 Gross profit (loss) 505,752 ( 2,608 ) 1,198,393 ( 2,608 ) Operating expenses: General and administrative 4,859,949 570,408 36,032,869 650,172 Sales and marketing 343,383 - 408,600 - Depreciation and amortization 802,796 - 1,605,668 - Total operating expenses 6,006,128 570,408 38,047,137 650,172 Loss from operations ( 5,500,376 ) ( 573,016 ) ( 36,848,744 ) ( 652,780 ) Other (expense), net ( 1,172,088 ) ( 1,309 ) ( 2,254,623 ) ( 4,667 ) Net loss $ ( 6,672,464 ) $ ( 574,325 ) $ ( 39,103,367 ) $ ( 657,447 ) All revenues were within the U.S. region. See Note 1, Organization and Summary of Significant Accounting Policies - Revenue Recognition for additional information about disaggregated revenue. 22 The Company’s long-lived tangible assets, as well as the Company’s operating lease right-of-use assets recognized on the condensed consolidated balance sheets were located as follows: June 30, December 31, 2025 2024 (unaudited) United States Property, plant and equipment, net $ 308,642 $ 388,180 Operating lease, right-of-use-assets $ 1,280,459 $ 1,528,128 Note 13. COMMITMENTS AND CONTINGENCIES From time to time, the Company is involved in legal proceedings arising from the normal course of business activities. The Company, in conjunction with its legal counsel, assesses the need to record a liability for litigation or loss contingencies. A liability is recorded when and if it is determined that such a liability for litigation or loss contingencies is both probable and estimable. Although the results of legal proceedings and claims cannot be predicted with certainty, the Company is not currently a party to any legal proceedings, which would, individually or in the aggregate, have a material adverse effect on its results of operations, cash flows, or financial position. On August 21, 2024, Blythe Global Advisors, LLC filed a demand for arbitration against the Company and Suren Ajjarapu for breach of contract, breach of the implied covenant of good faith and fair dealing, and breach of personal guaranty. Blythe claims to have performed accounting services for the Company in the amount of $ 377,947.36 for which it has not been paid and that Ajjarapu personally guaranteed payment of Blythe’s invoices. The Company has answered the arbitration demand and is vigorously defending the matter. Relatedly, in early 2025, Wellgistics, LLC, Wood Sage, LLC, Alliance Pharma Solutions, LLC, and Community Specialty Pharmacy, LLC, all subsidiaries of the Company, sued Blythe Global Advisors, LLC in the Circuit Court of the Thirteenth Judicial Circuit in and for Hillsborough County, Florida, asserting state statutory claims of improper UCC-1 filings, tortious interference with business relationships, slander of title, and state RICO violations. The Company claims that Blythe improperly filed a UCC-1 against the assets of these subsidiaries, when it only had a right file such a lien against the Company and that the filing impeded Wellgistics, LLC’s ability to secure a necessary credit line, causing substantial damages. Blythe filed a motion to dismiss that remains pending. The Company is vigorously prosecuting its claims. Note 14. SUBSEQUENT EVENTS Eighth Amendment to MIPA dated July 24, 2025 On July 24, 2025, the Company and the other parties to the Wellgistics MIPA further amended the Wellgistics MIPA to convert a cash payment of $ 8,139,259 owed by the Company to the former owners of Wellgistics, LLC, into approximately 7,606,785 shares of the Company’s common stock at the prevailing 3-day average weighted market price of $ 1.07 per share (the “Converted Shares”). The Company issued the Converted Shares effective July 24, 2025. The Eighth Amendment also increased the principal amount of the promissory notes issuable to the Wellgistics sellers from $ 15 million to $ 17.5 million, payable over three years with final maturity in July 2028. Hudson EPA As of July 25, 2025, the Company had exercised its put right to the aggregate 3,426,254 shares issuable to the investor currently registered for resale on its active Form S-1 Registration Statement (SEC File No. 333-286981). On August 13, 2025, the Company delivered written notice to the Investor of its election to terminate the Hudson EPA. Note Payable issued by Tollo Health, LLC, Tollo Health Inc. and Gerald Commissiong Tollo Health, LLC, Tollo Health Inc. and Gerald Commissiong (“ Borrowers ”), issued a Revolving Credit Note to Testing123, LLC dated March 12, 2025, in the original principal amount of up to $ 750,000 (the “Note”), pursuant to a Revolving Line of Credit Agreement. The obligations of the Borrowers under the Note were secured pursuant to the terms of the Pledge and Security Agreement of even date therewith and guaranteed by the Company pursuant to that certain Corporate Guaranty of even date therewith (the “ Guaranty ” and collectively with the Note, the Agreement, the Security Agreement, and the other documents executed in connection therewith, the “ Transaction Documents ”). Pursuant to the Transaction Documents, the initial advance under the Agreement in the amount of $ 444,600 was made on March 12, 2025. The term of the loan for this draw is two (2) months from the funding date, with a contractual maturity date of May 12, 2025. Interest accrues at the rate of five percent ( 5 %) per month, compounding monthly, and in the event of default, the applicable interest rate increases to ten percent ( 10 %) per month, also compounding monthly. Failure to pay any amount due on or before its maturity constitutes an event of default. The Borrowers defaulted on payment thereby migrating the liability to the Company as guarantor. On July 25, 2025, the Company paid the total amount owing under the obligation as Guarantors for the Borrowers in the amount of $ 640,647 in principal and interest directly to Testing123, LLC. One Big Beautiful Bill Act On July 4, 2025, President Donald J. Trump signed into law H.R. 1, the “One Big Beautiful Bill Act” (“The Act”). The Act includes many significant provisions, such as permanent extension of certain provisions of the Tax Cuts and Jobs Act, modifications to international tax provisions, and restoration of expensing for domestic research and development, among others. Certain provisions which impact the Company are effective starting in 2025, while others are not effective until 2026. The Company is currently evaluating the impact that The Act will have on its consolidated financial statements. 23 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. See “Cautionary Note Regarding Forward-Looking Statements” below. We have no obligation to update any of these forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements due to many factors, including, but not limited to, those set forth under the heading “Risk Factors” in this Quarterly Report. Factors that could cause or contribute to such differences include, but are not limited to, capital expenditures, economic and competitive conditions, regulatory changes and other uncertainties, as well as those factors discussed below and elsewhere in this Quarterly Report. Cautionary Statement Regarding Forward-Looking Information This Quarterly Report contains statements that constitute forward-looking statements that are subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Some of the statements in this Quarterly Report constitute forward-looking statements because they relate to future events or the future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. These forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” or the negative of these terms or other similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. 24 Forward-looking statements in this Quarterly Report may include, for example, statements about: ● A shift in pharmacy mix toward lower margin plans, margin compression on branded medications, or the increased offering of specialty products, direct and indirect remuneration fees, mail order pharmacy steering, and programs; ● Wellgistics Health deriving a portion of its sales from prescription drug sales reimbursed by pharmacy benefit management companies; ● Wellgistics Health being adversely affected by a decrease in the introduction of new brand name and generic prescription drugs as well as increases in the cost to procure prescription drugs; ● changes in economic conditions that adversely affect consumer/client buying practices and market adoption of our mobile application and the accompanying revenues to premium access/services; ● Wellgistics Health’s relationships with its primary wholesaler for pharmacy operations and Wellgistics Health’s manufacturer relationships of its wholesale and hub technology platform subsidiaries; ● changes in the healthcare industry and regulatory environments; ● the effects of competition on Wellgistics Health’s future business; ● Wellgistics Health’s ability to execute its business plans and strategy; and ● other risks and uncertainties described in the Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2025, and those risks described in the section entitled “ Risk Factors ” of this Quarterly Report and in other reports we file with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There can be no assurance that future developments affecting us will be those that we have anticipated. Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statements in this Quarterly Report should not be regarded as a representation by us that our plans and objectives will be achieved. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. We have based the forward-looking statements included in this Quarterly Report on information available to us on the date of this Quarterly Report, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements in this Quarterly Report, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we may file in the future with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Overview Incorporated in 2022, we are a holding company for operating companies centered around healthcare technology and pharmaceutical services. We seek to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. We strive to shift the dynamic of pharmaceutical care to revolve around the patient for a range of therapeutic conditions by offering various integrated solutions through leveraging our business segments to address access, care coordination, dispensing, delivery, and clinical management of certain pharmaceutical products. Currently, we own one direct operating company, Wellgistics, LLC, and two indirect operating companies, Wellgistics Tech & Hub, LLC dba DelivMeds (f/k/a Alliance Pharma Solutions, LLC) (“Wellgistics Tech & Hub”) and Wellgistics Pharmacy, LLC (f/k/a Community Specialty Pharmacy, LLC) (“Wellgistics Pharmacy”), through an intermediary—Wood Sage, LLC. 25 Wellgistics, LLC Founded in 2013, Wellgistics, LLC serves as the wholesale arm of our healthcare ecosystem as a 50-state FDA licensed and NABP-accredited pharmaceutical wholesaler distributor, bridging the gap between small- to mid-size pharmaceutical manufacturers and independent retail pharmacies. Serving over 5,000 registered pharmacies nationwide, Wellgistics, LLC provides significant value by offering competitive pricing, unique products, and exceptional service, while also promoting manufacturers’ products to a diverse range of pharmacies. Wellgistics, LLC’s primary focus is on supporting independent retail pharmacies in search of better products, prices, and services, thereby ensuring their growth and sustainability in the competitive pharmaceutical sector. Wellgistics, LLC provides distribution and third party logistics services to both pharmaceutical manufacturers and independent retail pharmacies. With over 60 manufacturing relationships, Wellgistics, LLC identifies niche therapeutic products and work with its manufacturing clients to increase market access and visibility of its client relationships with product awareness and support campaigns. Specifically, Wellgistics, LLC helps promote product distribution through its network of pharmacy buyers by providing sales and marketing support. These services include providing product education, identifying opportunities for therapeutic substitution when clinically relevant, and cost savings opportunities for pharmacies and their patients. Wellgistics, LLC’s portfolio of products is comprised of 65% topical generics with a primary focus on the dermatology market, 20% oral generic formulations primarily in the non-narcotic pain category, 10% oral and topical brand formulations, and 5% in the over-the-counter market space. Its investments in cold chain infrastructure will position this division to compete in the specialty-lite therapy category while also expanding our ability to house additional branded products. We acquired Wellgistics, LLC in August 2024. Wellgistics Tech & Hub, LLC dba DelivMeds (f/k/a Alliance Pharma Solutions, LLC ) Founded in 2017 under the name Alliance Pharma Solutions, LLC and doing business as DelivMeds, Wellgistics Tech & Hub serves as the middleware technology arm of our healthcare ecosystem by facilitating prescription transfer and clinical concierge services to a network of independent pharmacies. After conducting an extensive market research survey focusing on competition, Wellgistics Tech & Hub identified several key differentiators from other healthcare technology solutions, including various integrations of the hub with pharmacy management software systems and pharmacy point of sale systems, among others. This suggests that Wellgistics Tech & Hub could serve as an end-to-end patient-centric solution automating the prescription journey. Powered by Wellgistics Pharmacy as the backend pharmacy, Wellgistics Tech & Hub is the frontend technology serving as the middleware between all key stakeholders referenced in what we refer to as the 5P-Model: patients, providers, pharmacies, payors or pharmacy Benefit Managers, and pharmaceutical manufacturing companies. Through Wellgistics Tech & Hub, we aim to preserve patient autonomy, improve price transparency, and aid in making a meaningful impact on patient outcomes by eliminating barriers to therapy while simultaneously boosting adherence. We work with channel partners such as pharmaceutical manufacturers, provider groups and accountable care organizations, telehealth companies, and employer groups to offer full suite of patient-centered pharmacy services. Wellgistics Tech & Hub’s business-to-business strategy approach enables prescriptions to be sent directly to Wellgistics Pharmacy and subsequently transferred to an eligible in-network independent pharmacy. Each channel partner is equipped with de-identified data to improve its respective business operation and or improve its renumeration from the value-based services the clinical concierge arm provides. We acquired Wellgistics Tech & Hub through our acquisition of Wood Sage in June 2024. Wellgistics Pharmacy, LLC (f/k/a Community Specialty Pharmacy, LLC ) Founded in 2011, Wellgistics Pharmacy serves as the backbone dispensing pharmacy of our healthcare ecosystem. First operating as a retail community specialty pharmacy, Wellgistics Pharmacy provides general and specialty pharmacy services dedicated to servicing the needs of patients, as well as clinical expertise, technology-driven innovation tools, and administrative efficiencies that support physicians, payers, and pharmaceutical manufacturers. Initially focusing on providing HIV/AIDS products, Wellgistics Pharmacy has expanded its business operations to perform 340B services by partnering with local clinics and provider groups. It has pursued pharmacy state licenses to convert its business into a mail order pharmacy. Currently, Wellgistics Pharmacy is licensed in 32 states and the District of Columbia, with superb license coverage along the east coast. While Wellgistics Pharmacy voluntarily forfeited its specialty accreditations, Wellgistics Pharmacy maintains specialty internal standard operating procedures and performs all of the functions of a specialty pharmacy. 26 Wellgistics Pharmacy purchases pharmaceuticals including specialty medications from manufacturers and wholesale distributors, fills prescriptions, labels, packages and delivers these pharmaceuticals to patients’ homes or physicians’ offices through contract couriers or carriers. It maintains a call center and customer support within its pharmacy located in Tampa, Florida. Wellgistics Pharmacy has several 340B relationships, acting as the dispensing pharmacy for these healthcare facilities that help drive revenue and prescription volume. Wellgistics Pharmacy’s relationship with Wellgistics, LLC and other wholesalers enables it to offer a competitive cash-based formulary for the uninsured and underinsured patient populations. Given its low-cost business model, Wellgistics Pharmacy believes there is an opportunity to gain market share with small- to medium-size employer groups in a partnership model with other consumer driven healthcare companies to the extent that more patients elect to pay out of pocket for prescriptions. We acquired Wellgistics Pharmacy through our acquisition of Wood Sage in June 2024. Wellgistics Health, Inc. As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Our patient-centric approach combined with innovative healthcare applications positions us to shift the dynamic of care to revolve around the patient for a wide range of therapeutic conditions. We offer a full spectrum of integrated solutions by leveraging the synergies of our business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from “specialty-lite” to general maintenance conditions. Prior to acquiring Wood Sage, LLC, we did not generate revenue. As discussed above, we acquired Wellgistics Tech & Hub and Wellgistics Pharmacy through our acquisition of Wood Sage, LLC in June 2024, and acquired Wellgistics, LLC in August 2024. Currently, our revenues are derived from (i) pharmaceutical dispensing of products, (ii) care management services we deliver to patients and offer to pharmaceutical manufacturing clients, (iii) SaaS fees for use of our platform technology services, and (iv) product procurement and distribution to independent pharmacies. We expect that our ability to source and distribute pharmaceutical products to our pharmacy and network of independent pharmacy partners throughout the U.S. will adequately position us to negotiate greater discounts based on market share. Our management believes that our digital pharmacy, including its hub and clinical services technology platform, is poised to add significant value in the key specialty-lite market by providing patients access and convenience, while providing partners with ready-to-go market solutions with big data. Data released from the Centers for Medicare & Medicaid Services illustrates that the National Health Expenditure Data for 2022 grew to $4.5 trillion and accounted for 17.3% of gross domestic product (“GDP”), with an expected increase in the health spending share of GDP to 19.7% by 2032. A deeper dive of this report reveals that total retail prescription drug spending from 2021 to 2022 increased by 8.4% to $405.9 billion. IQVIA’S 2024 report on medicine spending trends found that overall spending in the U.S. market for medicines reached $435 billion in 2023. It is well documented in the literature that the specialty drug market accounts for less than 10% of total drugs in the market but is responsible for greater than 50% of the prescription drug spend per annum. After evaluating reasons for increased healthcare expenditure, poor medication adherence continues to be a challenge that causes unnecessary strain on the healthcare system, including, but not limited to, increased hospital admissions and readmissions rates from medication non-compliance and adverse events. Many of these factors are preventable by empowering patient autonomy in their healthcare journey, identifying cost savings opportunities, and providing access to clinical resources and support. We believe that our business model primely positions us to address the prescription spend in the “specialty lite” therapy area while improving patient health outcomes by equipping patients with our innovative digital health tools. We seek to expand the service coverage area of our pharmacy operations while strengthening its clinical expertise in several key therapeutic categories, including services such as care coordination and patient financial assistance. Furthermore, we expect that our partner relationships will enable us to offer a competitive cash formulary as an alternative option when high insurance deductibles make it economically feasible. We anticipate expanding our wholesale operations as we continue to partner and establish new manufacturer relationships. With many of these new relationships, we intend to provide sales and clinical education support to the pharmacies purchasing these products. We have strategically identified opportunities to wholesale products that are normally not carried by the three largest wholesalers in the United States, and will seek to carve out exclusivity or semi- exclusive relationships based on a time period to ensure we are maximizing our revenues. We expect that new partnerships with group purchasing organizations will be effective, as we increase the business divisions’ visibility with all or many of the member pharmacies. Our technology division will be connected to our pharmacy network enabling us to operate as a digital pharmacy and hub. Our pharmacy network leverages independent, locally-owned pharmacies that are rooted in their communities to create a powerful network of over 19,000 pharmacies across the United States capable of delivering prescriptions in hours. This channel services approximately 1.3 billion prescriptions annually and represents a $47 billion market at wholesale cost. 27 We seek to provide an end-to-end solution for digitizing the prescription journey through our Wellgistics Tech & Hub mobile application, which should help to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services in an effort to boost medication adherence and improve patient outcomes. We intend to aggregate the data collected from our solution to provide comprehensive reports that are tied to medication adherence and outcomes to make a meaningful impact for all stakeholders involved. We expect to monetize this valuable data with manufacturers, payors and providers. Pending Acquisition – Merger Agreement On April 8, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Wellgistics Health, Inc., Wellpeek Merger Sub 1, Inc. (“Merger Sub 1”), Wellpeek Merger Sub 2, LLC (“Merger Sub 2” and together with Merger Sub 1, the “Merger Subs”), Peek Healthcare Technologies, Inc. (“Peek”), and the Stockholder Representative (as defined in the Merger Agreement). Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), Merger Sub 1 will merge with and into Peek (the “First Merger”), with Peek continuing as the surviving entity and a wholly owned subsidiary of the Company. Immediately thereafter, Peek will merge with and into Merger Sub 2 (the “Second Merger” and, together with the First Merger, the “Mergers”), with Merger Sub 2 continuing as the surviving entity. The Mergers, taken together, are intended to constitute an integrated plan and be treated as a “reorganization” for U.S. federal income tax purposes. The board of directors and officers of Merger Sub 2 existing as of the Effective Time will serve as the board of directors and officers of Merger Sub 2, as the ultimate surviving entity. Peek is a pioneering digital prescription platform that seeks to transform how patients shop for medications by providing real-time pricing transparency to assist consumers with making more informed medication purchase decisions. Peek’s mission is to empower individuals with price transparency, innovative comparison tools, and seamless access to affordable prescriptions nationwide. Lumina Marketing, LLC, a Florida limited liability company (“Lumina Marketing”), and Lumina Therapeutics, LLC, a Delaware limited liability company (“Lumina Therapeutics” and, together with Lumina Marketing, the “Lumina Entities”) are affiliates of Peek and provide a range of consulting services to brand-name and specialty-lite drug manufacturers in the areas of market access, branding, and commercialization. As a condition to and prior to the closing of the Mergers, Peek will acquire all of the assets of each of the Lumina Entities in exchange for newly issued shares of Class A Common Stock of Peek (the “Lumina Contribution Shares”). Following closing of the transactions contemplated by the Merger Agreement, the legacy Peek and Lumina Entity businesses will operate under a single, wholly-owned subsidiary of the Company. At the effective time of the First Merger (the “First Effective Time”), the Lumina Contribution Shares that are issued and outstanding immediately prior to the First Effective Time will be converted into the right to receive Closing Merger Consideration as follows: ● A cash payment by the Company equal to $2,000,000, minus (i) the amount of Closing Indebtedness (as defined in the Merger Agreement), minus (ii) the amount of any unpaid Transaction Expenses (as defined in the Merger Agreement), plus (iii) the amount by which the Estimated Working Capital (as defined in the Merger Agreement) exceeds $150,000, or minus (iv) the amount by which the $150,000 exceeds the Estimated Working Capital; and ● An unsecured promissory note made by the Company (the “Note”) in the principal amount of $6,000,000 bearing interest at the rate of 4.5%, compounding annually, and maturing on the third anniversary of the date such note is made. 28 Also at the First Effective Time, all shares of Class A Common Stock of Peek (other than the Lumina Contribution Shares) and all shares of Class B Common Stock of Peek (collectively, the “Specified Shares”) that are issued and outstanding immediately prior to the First Effective Time will be converted into the right to receive 1,777,778 shares of Company common stock (the “Stock Consideration”) in Closing Merger Consideration as follows: ● 507,615 shares of Company common stock (the “Guaranteed Stock Consideration”); and ● 1,270,163 shares of Company common stock (the “Earn-Out Shares”), which shall be subject to forfeiture based on the Surviving Company’s ability to achieve the target aggregate revenue amount of $8,800,000 during the period commencing on the Closing Date and ending on December 31, 2027 . In order to preserve the intended U.S. federal income tax treatment of the Mergers, it is possible that all or a portion of the final payment under the Note may be made in the form of additional shares of Company common stock, depending on whether and the extent to which any Earn-Out Shares issued at the First Effective Time are forfeited pursuant to the terms of the Merger Agreement. The acquisition has not yet closed as of the issuance date of these financial statements included in this Quarterly Report. Key Components of Results of Operations We are an early-stage company, and our historical results may not be indicative of our future results for reasons that may be difficult to anticipate. Accordingly, the drivers of our future financial results, as well as the components of such results, may not be comparable to our historical or future results of operations. Revenues Wellgistics Health is a holding company specifically formed to hold operating companies. We did not generate any revenue prior to the Wood Sage Acquisition, but now expect to generate all of our revenues through DelivMeds, Wellgistics Pharmacy, and Wellgistics LLC. Although Wellgistics Health may add other sources of revenue through the acquisition of other operating companies in the future, Wellgistics Health currently does not have any such plans. Wellgistics Health will be subject to risk of specific inflationary pressures on product prices and its impact on consumer spending. For example, increases in prescription drug costs could impact consumers ability to afford initial or on-going therapy. Wellgistics Health’s focus on the relatively expensive specialty lite business segment (i.e., $500 - $3,000 therapies) could be particularly impacted by increasing costs. Additionally, consumer discretionary funds could be reduced, impacting the ability to pay for digital services and subscription models that Wellgistics Health offers. If inflation continues to increase, sourcing and procuring specialty lite products may prove to be capital intensive. Wellgistics Health may not be able to adjust prices sufficiently to offset the effect without negatively impacting consumer demand or Wellgistics Health’s gross margin. All of these inflationary risk factors could materially and adversely impact Wellgistics Health’s business operations, financial condition and results of operations. Wellgistics Pharmacy recognizes product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, when we transfer promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Wellgistics Pharmacy fills prescriptions for prescription and over-the-counter drugs written by a provider and recognizes revenue at the time the patient confirms the prescription order for payment of co-pays. 29 Expenses Sales and Marketing Expense Sales and marketing expenses consist of personnel and personnel-related expenses, including stock-based compensation for our business development team as well as trade events participation, public relations, white paper development, social media, pharmacy trade and patient materials, advertising, sales collateral, syndicated data fees, and other marketing expenses. We expect to increase our sales and marketing activities to grow our customer base and increase market share. We also expect that our sales and marketing expenses will increase over time as we continue to hire additional personnel to scale the business. General and Administrative Expense General and administrative expenses currently consist of business development, consulting, and information technology development and support and third-party software expenses. General and administrative expenses consist primarily of personnel-related costs (including salaries, bonuses, benefits, and stock-based compensation expense) for personnel in executive, finance, accounting, corporate development and other administrative functions. General and administrative expenses will also include legal fees, professional fees paid for accounting, auditing, consulting, tax, and investor relations services, insurance costs, facility costs not otherwise included in research and development expenses. Following Wellgistics Health’s registration as a public company, also include public company expenses such as costs associated with compliance with the rules and regulations of the SEC and the stock exchange. Income Tax (Benefit) Expense Our income tax provision will consist of an estimate for U.S. federal and state income taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in deferred tax assets and liabilities, and changes in the tax law. We will maintain a valuation allowance against the full value of our U.S. and state net deferred tax assets because we believe the recoverability of the tax assets is more likely than not. 30 Results of Operations For the Three Months Ended June 30, 2025 and 2024 Three Months Ended June 30, 2025 2024 Net revenues $ 7,790,865 $ 44,540 Cost of revenues 7,285,113 47,148 Gross profit (loss) 505,752 (2,608 ) General and administrative 4,859,949 570,408 Sales and marketing 343,383 - Depreciation and amortization 802,796 - Total operating expenses 6,006,128 570,408 Loss from operations (5,500,376 ) (573,016 ) Total other income (expense) (1,172,088 ) (1,309 ) Net loss (6,672,464 ) (574,325 ) Revenues and Cost of Revenues Net revenues were $7,790,865 for the three months ended June 30, 2025, consisting of revenue primarily derived from Wellgistics Pharmacy operations after the closings of the Wood Sage Acquisition on June 16, 2024 and the Wellgistics Acquisition August 30, 2024. Cost of revenues for the same period was $7,285,113. Gross profit was $505,752, representing a gross margin of 6.5%. For the three months ended June 30, 2024, the Company earned revenue of $44,540, with cost of revenues of $47,148, resulting in a gross loss of $2,608. The prior period figures reflect only partial revenue from Wood Sage operations for the period from June 16, 2024 to June 30, 2024, and do not include any revenue from Wellgistics. The following is a summary of the disaggregation of revenue for the three months ended June 30, 2025 and 2024: Three Months Ended June 30, 2025 2024 Product revenue - distribution services $ 7,548,600 $ - Pharmacy retail sales 77,756 44,540 Third party logistics services 164,509 - Net revenues $ 7,790,865 $ 44,540 General and Administrative Expense General and administrative expenses were $4,859,949 for the three months ended June 30, 2025, compared to $570,408 for the three months ended June 30, 2024. The increase was primarily due to the acquisition of Wellgistics LLC in August 2024 and full-scale operations of the consolidated company in 2025. General and administrative expenses include personnel costs, and professional fees including audit, tax and legal. For the three months ended June 30, 2025, general and administrative expenses also included $870,005 of non-cash stock-based compensation related to the issuance of restricted common stock to directors, employees, and consultants in exchange for services rendered. Sales and Marketing Expense Sales and marketing expenses were $343,383 for the three months ended June 30, 2025, compared to $0 for the same period in 2024. The increase reflects the Company’s expanded promotional activities and marketing initiatives following the acquisitions of Wood Sage and Wellgistics LLC. For the three months ended June 30, 2025, sales and marketing expenses also included $65,217 of non-cash stock-based compensation 31 Depreciation and Amortization Depreciation and amortization was $802,796 for the three months ended June 30, 2025, compared to $0 for the three months ended June 30, 2024. This included amortization of $763,065 pertaining to intangible assets identified from acquisitions of Wood Sage and Wellgistics, LLC. Depreciation expense of $39,731 relates to fixed assets acquired from the Wellgistics LLC acquisition. Interest Expense Interest expense was $1,184,040 and $1,309 for the three months ended June 30, 2025 and 2024, respectively. Interest expense in 2025 was incurred on Wellgistics Health’s outstanding loans, promissory notes, revolving line of credit and merchant cash advance agreements. For the Six Months Ended June 30, 2025 and 2024 Six Months Ended June 30, 2025 2024 Net revenues $ 18,654,308 $ 44,540 Cost of revenues 17,455,915 47,148 Gross profit 1,198,393 (2,608 ) General and administrative 36,032,869 650,172 Sales and marketing 408,600 - Depreciation and amortization 1,605,668 - Total operating expenses 38,047,137 650,172 Loss from operations (36,848,744 ) (652,780 ) Total other income (expense) (2,254,623 ) (4,667 ) Net loss (39,103,367 ) (657,447 ) Revenues and Cost of Revenues Net revenues were $18,654,308 for the six months ended June 30, 2025, consisting of revenue primarily derived from Wellgistics Pharmacy operations after the closings of the Wood Sage Acquisition on June 16, 2024 and the Wellgistics Acquisition August 30, 2024. Cost of revenues for the same period was $17,455,915. Gross profit was $1,198,393, representing a gross margin of 6.4%. For the six months ended June 30, 2024, the Company earned revenue of $44,540, with cost of revenues of $47,148, resulting in a gross loss of $2,608. The prior period figures reflect only partial revenue from Wood Sage operations for the period from June 16, 2024 to June 30, 2024, and do not include any revenue from Wellgistics, LLC. The following is a summary of the disaggregation of revenue for the six months ended June 30, 2025 and 2024: Six Months Ended June 30, 2025 2024 Product revenue - distribution services $ 18,216,887 $ - Pharmacy retail sales 192,432 44,540 Third party logistics services 244,989 - Net revenues $ 18,654,308 $ 44,540 32 General and Administrative Expense General and administrative expenses were $36,032,869 for the six months ended June 30, 2025, compared to $650,172 for the six months ended June 30, 2024. The increase was primarily due to the acquisition of Wellgistics LLC in August 2024 and full-scale operations of the consolidated company in 2025. General and administrative expenses include personnel costs, and professional fees including audit, tax and legal. For the six months ended June 30, 2025, general and administrative expenses also included $28,308,643 of non-cash stock-based compensation related to the issuance of common stock to directors, employees, and consultants in exchange for services rendered. Sales and Marketing Expense Sales and marketing expenses were $408,600 for the three months ended June 30, 2025, compared to $0 for the same period in 2024. The increase reflects the Company’s expanded promotional activities and marketing initiatives following the acquisitions of Wood Sage and Wellgistics. For the six months ended June 30, 2025, sales and marketing expenses also included $400,000 of non-cash stock-based compensation. Depreciation and Amortization Depreciation and amortization was $1,605,668 for the six months ended June 30, 2025, compared to $0 for the six months ended June 30, 2024. This included amortization of $1,526,130 pertaining to intangible assets identified from acquisitions of Wood Sage and Wellgistics, LLC. Depreciation expense of $79,538 relates to fixed assets acquired from the Wellgistics acquisition. Interest Expense Interest expense was $2,278,530 and $4,667 for the six months ended June 30, 2025 and 2024, respectively. Interest expense in 2025 was incurred on Wellgistics Health’s outstanding loans, promissory notes, revolving line of credit and merchant cash advance agreements. Liquidity and Capital Resources Our future cash needs are expected to include cash for operating activities, working capital, purchases of property and equipment, strategic investments, development, and expansion of facilities. We will fund our operations primarily through operating cash flows, the issuance of debt and the sale of equity securities. In order to proceed with our business plan, we may need to raise additional funds through the issuance of debt, equity or other commercial arrangements that may not be available to us when needed or on terms that we deem favorable. To the extent we raise additional capital through the sale of equity or convertible securities, our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we are unable to obtain sufficient financial resources, our business, financial condition and results of operations may be materially and adversely affected. We may be required to delay, limit, reduce or terminate parts of its strategic business plan or future commercialization efforts. There can be no assurance that we will be able to obtain financing on acceptable terms. Our short-term liquidity requirements include initiatives related to the (i) expansion of existing facilities and upgrade of equipment in order to increase operational capacity, (ii) recruitment of additional employees to increase operational and business needs, upgrade of information technology, and (iii) continued buildout of corporate functions and public company compliance requirements, inclusive of accounting and legal fees. Our long-term liquidity requirements include initiatives related to (a) strategic acquisitions mean to further the development of our health ecosystem such as electronic health record systems, (b) expansion of micro-distribution centers for wholesale and other wholly owned pharmacies in strategic demographic regions, (c) investments into artificial intelligence, machine learning, and data warehousing capabilities, and (d) additional integrations with third-party partners such as PMS systems, ride-sharing logistics providers, enterprise health systems, and others to bolster the value proposition of our health ecosystem with a focus on improving operational efficiency while simultaneously removing interdependencies. 33 Equity Purchase Agreement As of June 30, 2025, the Company had issued a total of 1,155,030 shares of common stock pursuant to put notices under the Hudson EPA, resulting in net proceeds of $1,149,417. As of June 30, 2025, the Company had a subscription receivable of $581,595 pertaining to shares issued under the Equity Purchase Agreement for which proceeds were received in July 2025. In August 2025, the parties terminated the Hudson EPA. Debt Outstanding debt consists of the following: June 30, December 31, 2025 2024 Merchant cash advance, net of debt discount $ 1,548,657 $ 1,259,415 Loan payable 703,366 - Note payable - sellers of Wellgistics 5,000,000 5,000,000 Note payable, net of debt discount 648,411 - Note payable – Integral Health 1,300,000 - Revolving line of credit 3,979,766 5,531,260 Seller promissory note - 137,141 Current portion of debt obligations 13,180,200 11,927,816 Merchant cash advance $ - $ 55,085 Third party investor 100,000 100,000 Note payable - Integral Health - 1,300,000 Note payable - sellers of Wellgistics 10,000,000 10,000,000 Long-term debt 10,100,000 11,455,085 Total debt $ 23,280,200 $ 23,382,901 Integral Health Inc. On August 22, 2023, Wood Sage entered into a non-interest bearing promissory note (“Note”) with Integral Health, a then related party with common ownership and board members, pursuant to which Integral made a certain loan to Wood Sage in the amount of $1,300,000 to satisfy the purchase price under the agreements by which Wood Sage acquired Wellgistics Pharmacy and DelivMeds. No later than 30 days after a change in control to Wood Sage, the aggregate unpaid principal balance of the Note became due and payable by Wood Sage. As of the date of these financial statements, the note is still outstanding and the parties mutually agreed for an extension. Merchant Cash Advance On March 18, 2025, the Company entered into a merchant cash advance agreement with a third-party lender. Pursuant to the agreement, the Company received gross funding of $1,900,000 in exchange for the sale of future receivables totaling $2,840,000. Of the $1,900,000 in funding, $1,118,250 was directly applied by the lender to settle existing obligations under a prior agreement with the same lender, effectively refinancing the earlier balance. The remaining $781,750 was disbursed to the Company for working capital and operational needs. 34 The MCA Agreement resets the Purchased Amount (as defined), repayment terms, and structure under a new contract. The Company is obligated to remit weekly payments of $56,800 until the full Purchased Amount of $2,840,000 is repaid. The Company accounts for the merchant cash advance as a debt obligation. The Company recorded a liability equal to the full Purchased Amount of $2,840,000, with a corresponding debt discount of $940,000 representing the difference between the repayment obligation and the net proceeds received. The debt discount will be amortized to interest expense over the term of the arrangement. As of June 30, 2025, the carrying amount of the loan, net of the remaining unamortized discount of $552,943, was $1,548,657. Loan Payable On May 14, 2025, the Company entered into a Business Loan and Security Agreement with Agile Capital Funding, LLC for a principal amount of $756,000. The Company received $500,000 in cash proceeds and recorded a debt discount of $256,000. The loan does not bear a stated interest rate; instead, the debt discount represents the implied borrowing cost. The loan matures in December 2025, and is repayable in weekly installments of $27,000. The loan is secured by certain assets of the Company not otherwise secured in its other financing arrangements and was used for general working capital purposes. The Company is amortizing the debt discount using the effective interest method over the 28 week term. Amortization of debt discount recorded to interest expense was $45,542 for the three and six months ended June 30, 2025. As of June 30, 2025, the carrying amount of the loan, net of the remaining unamortized discount of $210,458, was $464,542. Cash Advance On June 25, 2025, the Company entered into an Agreement for the Purchase and Sale of Future Receipts with Agile Capital Funding, LLC for a total purchased amount of $367,200. The Company received $255,000 in cash proceeds and recorded a debt discount of $112,200. The agreement assigns 15% of proceeds of future sales to the buyer, with weekly repayment installments of $13,144 over 28 weeks based on estimated average monthly sales projections. Proceeds were used for general working capital purposes. The Company is amortizing the debt discount using the effective interest method over the 28 week term. As of June 30, 2025, the carrying amount of the arrangement, net of the remaining unamortized discount of $112,200, was $238,824. Note payable – owners of Wellgistics, LLC On August 23, 2024, the Company and the sellers of Wellgistics LLC entered into the Fourth Amendment to the Wellgistics MIPA. Pursuant to the amended agreement, Wellgistics Health agreed to pay Wellgistics LLC a promissory note in the aggregate principal amount of $15,000,000 plus simple interest accruing annually equal to the “Prime Rate” as published by the Wall Street Journal on January 1 of the applicable year, together payable in three equal annual installments commencing on the first anniversary of the date that IPO registration statement becomes effective. For 2025, the interest rate was 7.5%. For the three and six months ended June 30, 2025, the Company recorded interest expense of $318,750 and $637,500, respectively, pertaining to the note. As of June 30, 2025 and December 31, 2024, accrued interest on the note totaled $1,062,500 and $425,000 respectively, and is included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. As of June 30, 2025, $5,000,000 was included as a current liability on the consolidated balance sheet and the remaining $10,000,000 was classified as non-current. Note Payable – Third Party On January 2, 2025, the Company entered into an unsecured promissory note agreement for a principal amount of $448,411. The promissory note bears interest at a rate of 10% per annum, with both principal and accrued interest due in full on May 15, 2025. In the event of default, interest accrues at a default rate of 12% per annum. In connection with this note, the Company received net proceeds of $415,000, with the remaining $33,411 recognized as a debt discount. For the three months ended June 30, 2025, the Company recorded interest expense of $11,210 and amortization of debt discount of $11,304 related to this note. For the six months ended June 30, 2025, the Company recorded total interest expense of $22,021 and amortization of debt discount of $33,411. As of June 30, 2025, accrued interest payable on this note was $22,021, and the outstanding principal of $448,411 is classified under current liabilities. As of the issuance date of these financial statements, the parties are currently working on an extension. On February 2, 2025, the Company entered into an unsecured promissory note agreement for a principal amount of $100,000. The promissory note bears interest at a rate of 10% per annum, with both principal and accrued interest due in full on August 15, 2025. In the event of default, interest accrues at a default rate of 12% per annum. For the three months ended June 30, 2025, the Company recorded interest expense of $2,500 related to this note. For the six months ended June 30, 2025, the Company recorded total interest expense of $4,062. As of June 30, 2025, accrued interest payable on this note was $4,062, and the outstanding principal of $100,000 is classified under current liabilities. As of the issuance date of these financial statements, the parties are currently working on an extension. On February 2, 2025, the Company entered into another unsecured promissory note agreement in the principal amount of $100,000. The promissory note bears interest at a rate of 10% per annum, with both principal and accrued interest due in full on August 15, 2025. In the event of default, interest accrues at a default rate of 12% per annum. For the six months ended June 30, 2025, the Company recorded interest expense of $4,062 related to this promissory note. As of June 30, 2025, the outstanding principal of $100,000 is classified under current liabilities. As of the issuance date of these financial statements, the parties are currently working on an extension. Note Payable – Related Party On April 7, 2025, the Company issued an unsecured promissory note (the “April 2025 Note”) to Sansur Associates, LLC, a related party entity beneficially owned by Surendra Ajjarapu, the Chairman of the Company’s Board of Directors, in the principal amount of $500,000. The April 2025 Note bears interest at a rate of 10% per annum and matures on October 7, 2025. The Company may prepay any portion of the outstanding principal and accrued interest at any time without penalty. In the event of a default, the note provides for acceleration of the outstanding balance and an increase in the interest rate to 12% per annum. As of June 30, 2025, the principal amount had not been funded and no interest expense had accrued. The April 2025 Note was subsequently canceled in August 2025. Revolving line of credit In November 2024, the Company entered into a new credit agreement for a line of credit of $10,000,000. The new line of credit has interest annual rate equal to the Term SOFR plus 11.5% , calculated and prorated daily on the daily balance (an aggregate rate of 16.84% per annum). The line of credit is collateralized by accounts receivable and inventory balances. Interest related to the line of credit amounted to $332,439 and $614,199 for the three and six months ended June 30, 2025, respectively. The outstanding balance on the line of credit as of June 30, 2025 and December 31, 2024 was $3,979,766 and $5,531,260, respectively, which is included as a current liability on the consolidated balance sheet. 35 Seller Promissory Note - Wellgistics In May 2022, the Company entered into a promissory note agreement in the amount of $1.2 million. The promissory note was part of the consideration to the seller in connection with its acquisition of American Pharmaceutical Ingredients, LLC (a subsidiary of Wellgistics LLC). The promissory note bore interest at a rate of 2% per annum and scheduled to mature on April 1, 2025. The Company assumed this debt as part of the Wellgistics Acquisition. As of June 30, 2025, the promissory note had been fully repaid, and the outstanding balance was $0, compared to $137,141 as of December 31, 2024. Interest expense related to the promissory note was immaterial for the six months ended June 30, 2025. The following table is a summary of annual principal payments of the Company’s outstanding debt: December 31, 2025 $ 14,060,801 2026 5,100,000 2027 5,000,000 $ 24,160,801 Dividends We intend to retain future earnings, if any, for future operations, expansion and debt repayment (if any) and we have no current plans to pay any cash dividends for the foreseeable future. In addition, our ability to pay dividends is likely to be limited by covenants of any future indebtedness. There are no, and we do not intend in the future for there to be any, restrictions in the covenants of any existing and outstanding indebtedness on our wholly-owned subsidiaries from distributing earnings in the form of dividends, loans or advances and through repayment of loans or advances to us. 36 Cash Flows The following table summarizes our cash flows from operating, investing, and financing activities : Six Months Ended June 30, 2025 2024 Net cash (used in) provided by operating activities $ (3,426,447 ) $ 361,193 Net cash used in investing activities $ (405,059 ) $ (17,545 ) Net cash provided by financing activities $ 3,223,112 $ (278,037 ) Net change in cash and cash equivalents $ (608,394 ) $ 65,611 Cash from operating activities Net cash used in operating activities for the six months ended June 30, 2025 was $3,426,447, primarily due to our net loss of $39,103,367, partially offset by non-cash expenses of $30,548,175 and $5,128,743 in cash provided in operating assets and liabilities. Non-cash expenses was driven by stock-based compensation of $28,708,643. Cash provided by operating assets and liabilities was primarily driven by an increase in accounts payable of $3,141,895. Net cash provided by operating activities for the six months ended June 30, 2024 was primarily a result changes in operating assets and liabilities of $1,005,846, partially offset by our net loss of $657,447 and non-cash expenses of $12,794. Cash from investing activities Net cash used in investing activities for the six months ended June 30, 2025, was $405,059 due to expenditures made for capitalized software. Cash from financing activities Net cash provided by financing activities for the six months ended June 30, 2025, was $3,223,112. This was primarily driven by gross proceeds of $4,000,000 from the issuance of common stock in our IPO, $567,722 from common stock issuances under our equity purchase agreement, $615,000 from promissory notes, and $234,157 in net proceeds from a merchant cash advance. These inflows were partially offset by $1,208,498 in offering costs, as well as repayments of a note payable and revolving line of credit. Net cash used in financing activities for the six months ended June 30, 2024 consists of $10,000 in proceeds from common stock to be issued, and $288,037 in offering costs incurred. Off-Balance Sheet Arrangements During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules. 37 Critical Accounting Policies and Estimates Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. Preparation of the financial statements requires our management to make a number of judgments, estimates and assumptions relating to the reported amount of expenses, assets and liabilities and the disclosure of contingent assets and liabilities. We consider an accounting judgment, estimate or assumption to be critical when (i) the estimate or assumption is complex in nature or requires a high degree of judgment and (ii) the use of different judgments, estimates and assumptions could have a material impact on our consolidated financial statements. Our significant accounting policies are described in Note 1 to our financial statements included elsewhere in this proxy statement/prospectus. Our critical accounting policies include: Revenue Recognition The Company adopted Accounting Standards Codification (“ASC”) 606 upon inception. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract was determined to be within the scope of ASC 606, the Company assessed the goods or services promised within each contract and determined those that were performance obligations, and assessed whether each promised good or service was distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. The Company recognizes revenue at the point of sale. The majority of orders are placed via the Company’s website. Customers generally pay by credit card at the time they place their order. The Company does have larger customers to whom they have extended terms for payment. Generally, payments from these customers are due within 30 days of their order being shipped. However, a few customers have been given terms extending out to 45 days. Distribution Wellgistics, LLC provides distribution and third party logistics services to both pharmaceutical manufacturers and independent retail pharmacies. The Company recognizes revenue when goods are delivered to the customer. The gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are considered when estimating the impact of these revenue deductions on gross sales for a reporting period. All revenue for the Company is recognized at the point-in-time when delivered to customer based on contractual obligations. Any amount collected from customers for goods not yet delivered is recorded as unearned revenue. Wellgistics Pharmacy The Company is in the retail pharmacy business. and fills prescriptions for drugs written by a doctor and recognizes revenue at the time the patient confirms delivery of the prescription. Customer returns are not material. The following are the steps taken to recognize revenue. 38 Step One: Identify the contract with the customer — The prescription is written by a doctor for a customer and delivered to the Company. The prescription identifies the performance obligations in the contract. The Company fills the prescription and delivers the prescription to the customer, fulfilling the contract. The collection is probable because there is confirmation that the customer has insurance for the reimbursement to the Company prior to filling of the prescription. Step Two: Identify the performance obligations in the contract — Each prescription is distinct to the customer. Step Three: Determine the transaction price — The consideration is not variable. The transaction price is determined to be the price of the prescription at the time of delivery which considers the expected reimbursements from third party payors (e.g., pharmacy benefit managers, insurance companies and government agencies). Step Four: Allocate the transaction price — The price of the prescription invoiced represents the expected amount of reimbursement from third party payors. There is no difference between contract price and “stand-alone selling price”. Step Five: Recognize revenue when or as the entity satisfies a performance obligation — Revenue is recognized upon the delivery of the prescription. Business Combinations The Company accounts for acquisitions in which it obtains control of one or more businesses as a business combination. The purchase price of the acquired businesses is allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The excess of the purchase price over those fair values is recognized as goodwill. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments, in the period in which they are determined, to the assets acquired and liabilities assumed with the corresponding offset to goodwill. If the assets acquired are not a business, the Company accounts for the transaction or other event as an asset acquisition. Under both methods, the Company recognizes the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity. In addition, for transactions that are business combinations, the Company evaluates the existence of goodwill or a gain from a bargain purchase. Item 3. Quantitative and Qualitative Disclosures About Market Risk. The Company is not required to provide the information required by this Item 3 as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures As of June 30, 2025, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2025, due to the material weakness described below. Material Weakness In its assessment of the effectiveness of internal control over financial reporting as of June 30, 2025, management identified material weaknesses in control environment, risk assessment, control activities, information and communication and monitoring. Specifically, the material weaknesses identified relate to the fact that the Company has not yet designed and maintained an effective control environment commensurate with its financial reporting requirements, including (a) has not yet completed formally documenting policies and procedures with respect to review, supervision and monitoring of the Company’s accounting and reporting functions, (b) lack of evidence to support the performance of controls and the adequacy of review procedures, including the completeness and accuracy of information used in the performance of controls and (c) we have limited accounting personnel and other supervisory resources necessary to adequately execute the Company’s accounting processes and address its internal controls over financial reporting. Plan for Remediation To remediate this material weakness, management is implementing the following measures: ● Hiring additional accounting personnel with appropriate technical expertise; ● Enhancing internal review procedures for complex transactions; ● Providing targeted training to existing finance staff on U.S. GAAP and SEC reporting requirements; ● Upgrading to NetSuite’s enterprise resource program; and Management expects these remediation efforts to be completed during fiscal year 2025, subject to the timing of hiring and training. Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting during the quarter ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, other than the remediation measures described above. 39 PART II—OTHER INFORMATION Item 1. Legal Proceedings. None. Item 1A. Risk Factors. Except with respect to the Company’s on-going liquidity needs, there were no material changes in the risk factors we previously disclosed in Item 1A to Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on April 1, 2025. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Unregistered Sales of Equity Securities Set forth below is information regarding securities that we issued during the six months ending June 30, 2025, that were not registered under the Securities Act of 1933, as amended, (the “Securities Act”) and not previously disclosed in reports filed with the SEC. Also included is the consideration received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. On June 26, 2025, the Company issued 750,000 shares of restricted common stock to former chief executive officer Timothy Canning as consideration for the sign-on bonus deliverable to the terms of his employment agreement, which terminated upon his resignation in February 2025. These restricted shares vest on December 26, 2025. As of June 30, 2025, the Company had issued a total of 1,155,030 shares of common stock pursuant to put notices under the Hudson EPA, resulting in net proceeds of $1,149,417. The forgoing issuances were not registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. In each transaction, we did not engage in any general solicitation or advertising and we offered the securities to a limited number of persons with whom we had pre-existing relationships. We exercised reasonable care to ensure that the purchasers of securities were not underwriters within the meaning of the Securities Act, including making reasonable inquiry prior to the issuances, making written disclosure regarding the restricted nature of the securities, and placing a legend on the certificates representing the shares. The recipients of securities in each of these transactions acquired the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof. No underwriters were involved in the above transactions. Repurchases None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. During the quarter ended June 30, 2025, none of the Company’s directors or officers adopted , modified , or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K. 40 Item 6. Exhibits. The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report. Exhibit Number Description 2.1** Agreement and Plan of Merger dated April 8, 2025, by and among Wellgistics Health, Inc., Wellpeek Merger Sub 1, Inc., Wellpeek Merger Sub 2, LLC, Peek Healthcare Technologies, Inc., and the Stockholder Representative (incorporated by reference to exhibit 2.1 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on April 11, 2025). 2.2 Seventh Amendment to Membership Interest Purchase Agreement dated April 14, 2025, by and among Wellgistics Health, Inc. (f/k/a Danam Health, Inc.), Wellgistics, LLC, Strategix Global LLC, Nomad Capital LLC, Jouska Holdings LLC, and Brian Norton, as amended (incorporated by reference to exhibit 2.1 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on April 18, 2025). 2.3 Eighth Amendment to Membership Interest Purchase Agreement dated July 24, 2025, by and among Wellgistics Health, Inc. (f/k/a Danam Health, Inc.), Wellgistics, LLC, Strategix Global LLC, Nomad Capital LLC, Jouska Holdings LLC, and Brian Norton as Seller Representative, as amended (incorporated by reference to exhibit 2.1 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on July 29, 2025). 3.1 Certificate of Incorporation of Wellgistics Health, Inc., as amended and currently in effect (incorporated by reference to Exhibit 3.1 of Wellgistics Health, Inc.’s amended Registration Statement on Form S-1/A filed with the SEC on January 14, 2025) . 3.2 Bylaws of Wellgistics Health, Inc. as currently in effect (incorporated by reference to Exhibit 3.2 of Wellgistics Health, Inc.’s amended Registration Statement on Form S-1/A filed with the SEC on January 14, 2025) . 10.1 Promissory Note made by Wellgistics Health, Inc. dated April 4, 2025 (incorporated by reference to Exhibit 10.1 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on April 11, 2025) . 10.2 Equity Purchase Agreement by and between Wellgistics Health, Inc. and Hudson Global Ventures, LLC, dated April 9, 2025 (incorporated by reference to Exhibit 10.2 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on April 11, 2025) . 10.3 Registration Rights Agreement by and between Wellgistics Health, Inc. and Hudson Global Ventures, LLC, dated April 9, 2025 (incorporated by reference to Exhibit 10.3 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on April 11, 2025) . 10.4† Executive Employment Agreement dated April 22, 2025, by and between the Company and Mark DiSiena (incorporated by reference to Exhibit 10.1 of Wellgistics Health, Inc.’s Current Report on Form 8-K filed with the SEC on April 24, 2025). 10.5*# Business Loan and Security Agreement dated as of May 14, 2025, among Agile Capital Funding, LLC, Wellgistics Health, Inc., and Wellgistics, LLC. 10.6*#** Agreement for the Purchase and Sale of Future Receipts dated June 25, 2025 by and between Wellgistics Health, Inc. and Agile Capital Funding, LLC. 31.1* Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2* Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 104* Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101) * Furnished herewith. ** As permitted by Regulation S-K, Item 601(b)(10)(iv) of the Securities Exchange Act of 1934, as amended, certain confidential portions of this exhibit have been redacted from the publicly filed document. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request. † Indicates a management contract or any compensatory plan, contract or arrangement. # Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. 41 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WELLGISTICS HEALTH, INC. By: /s/ Mark DiSiena Name: Mark DiSiena Title: Chief Financial Officer (Principal Financial Officer and Accounting Officer) Date: August 19, 2025 42